{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T18:10:10Z","timestamp":1752171010756,"version":"3.41.2"},"posted":{"date-parts":[[2025,7,10]]},"group-title":"In Review","reference-count":72,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,6,26]]},"abstract":"<title>Abstract<\/title>\n        <p><bold>Background:<\/bold>\nThe accumulation and aggregation of amyloid beta (A\\(\\beta\\))---a peptide fragment derived from the proteolytic processing of amyloid precursor protein (APP)---is a central pathological feature of Alzheimer\u2019s disease (AD) and a current target for disease-modifying therapies. Mutations in APP can also drive early-onset AD. While the roles of \\(\\alpha\\)-, $\\beta$-, and \\(\\gamma\\)-secretases and their respective cleavage sites in APP processing are well characterized, much less is understood about the routine degradation of APP within sub-cellular compartments like the lysosome.\n<bold>Methods:<\/bold>\nWe applied Multiplexed Substrate Profiling by Mass Spectrometry (MSP-MS) to map cleavage sites within APP that may be targeted by lysosomal proteases, also known as cathepsins. We then employed cell-based and in vitro\nassays to examine the degradation of both wild-type and mutant APP by these enzymes.\n<bold>Results:<\/bold>\nOur findings confirm that APP is enriched in the endo-lysosomal compartment, where it is processed by many, but not all, cathepsins. Our experiments reveal that cleavages at several mapped APP sites are sensitive to both changes in pH and the presence of pathogenic variants E693G and E693Q. Additionally, we discovered that the large soluble domain of APP (sAPP) enhances tau cleavage by cathepsin G in vitro.\n<bold>Conclusions:<\/bold>\nCollectively, these results underscore the importance of lysosomal processing of APP, identify a link between APP and tau, and suggest new avenues for exploring AD pathogenesis. They also point to potential therapeutic targets related to the lysosomal function of APP and its impact on neurodegenerative disease.<\/p>","DOI":"10.21203\/rs.3.rs-6978813\/v1","type":"posted-content","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T07:16:53Z","timestamp":1752131813000},"source":"Crossref","is-referenced-by-count":0,"title":["Lysosomal Protease-Mediated APP Degradation is pH-Dependent, Mutation-Sensitive, and Facilitates Tau Proteolysis"],"prefix":"10.21203","author":[{"given":"Caroline","family":"Ackley","sequence":"first","affiliation":[{"name":"University of California San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoe","family":"Liau","sequence":"additional","affiliation":[{"name":"University of California San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shruti","family":"Arya","sequence":"additional","affiliation":[{"name":"University of California San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara","family":"Antee","sequence":"additional","affiliation":[{"name":"University of California San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giselle M.","family":"Knudsen","sequence":"additional","affiliation":[{"name":"Alaunus Biosciences, Inc, South San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney","family":"Lane-Donovan","sequence":"additional","affiliation":[{"name":"University of California San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J.","family":"Sampognaro","sequence":"additional","affiliation":[{"name":"University of California San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aimee W.","family":"Kao","sequence":"additional","affiliation":[{"name":"University of California San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Tamargo, Rafael J. and Velayati, Arash and Goldin, Ehud and Sidransky, Ellen (2012) The role of saposin {C} in {Gaucher} disease. Molecular genetics and metabolism 106(3): 257--263 https:\/\/doi.org\/10.1016\/j.ymgme.2012.04.024, PMC3534739, 22652185, July, 2025-06-12, Saposin C is one of four homologous proteins derived from sequential cleavage of the saposin precursor protein, prosaposin. It is an essential activator for glucocerebrosidase, the enzyme deficient in Gaucher disease. Gaucher disease is a rare autosomal recessive lysosomal storage disorder caused by mutations in the GBA gene that exhibits vast phenotypic heterogeneity, despite its designation as a  \u201csimple \u201d Mendelian disorder. The observed phenotypic variability has led to a search for disease modifiers that can alter the Gaucher phenotype. The PSAP gene encoding saposin C is a prime candidate modifier for Gaucher disease. In humans, saposin C deficiency due tomutations in PSAP results in a Gaucher-like phenotype, despite normal in vitro glucocerebrosidase activity. Saposin C deficiency has also been shown to modify phenotype in one mousemodel of Gaucher disease. The role of saposin C as an activator required for normal glucocerebrosidase function, and the consequences of saposin C deficiency are described, and are being explored as potential modifying factors in patients with Gaucher disease., https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3534739\/, 1096-7192","DOI":"10.1016\/j.ymgme.2012.04.024"},{"key":"ref2","unstructured":"Butler, Victoria J. and Cortopassi, Wilian A. and Argouarch, Andrea R. and Ivry, Sam L. and Craik, Charles S. and Jacobson, Matthew P. and Kao, Aimee W. (2019) Progranulin {Stimulates} the {In} {Vitro} {Maturation} of {Pro}-{Cathepsin} {D} at {Acidic} {pH}. Journal of Molecular Biology 431(5): 1038--1047 https:\/\/doi.org\/10.1016\/j.jmb.2019.01.027, Accepted Version:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\A5AER77Q\\\\Butler et al. - 2019 - Progranulin Stimulates the In Vitro Maturation of .pdf:application\/pdf, cathepsin D, Cathepsin D, Cell Line, Enzyme Precursors, Frontotemporal Lobar Degeneration, HEK293 Cells, Humans, Hydrogen-Ion Concentration, maturation, Mutation, neurodegeneration, Neuronal Ceroid-Lipofuscinoses, progranulin, Progranulins, propeptide, PMC6613950, 30690031, March, eng, Single-copy loss-of-function mutations in the progranulin gene (PGRN) underlie the neurodegenerative disease frontotemporal lobar degeneration, while homozygous loss-of-function of PGRN results in the lysosomal storage disorder neuronal ceroid lipofuscinosis. Despite evidence that normal PGRN levels are critical for neuronal health, the function of this protein is not yet understood. Here, we show that PGRN stimulates the in vitro maturation of the lysosomal aspartyl protease cathepsin D (CTSD). CTSD is delivered to the endolysosomal system as an inactive precursor (proCTSD) and requires sequential cleavage steps via intermediate forms to achieve the mature state (matCTSD). In co-immunoprecipitation experiments, PGRN interacts predominantly with immature pro- and intermediate forms of CTSD. PGRN enhances in vitro conversion of proCTSD to matCTSD in a concentration-dependent manner. Differential scanning fluorimetry shows a destabilizing effect induced by PGRN on proCTSD folding ( \u2206Tm \u202f= \u202f-1.7 \u202f \u00b0C at a 3:1 \u202fmolar ratio). We propose a mechanism whereby PGRN binds to proCTSD, destabilizing the propeptide from the enzyme catalytic core and favoring conversion to mature forms of the enzyme. Further understanding of the role of PGRN in CTSD maturation will assist in the development of targeted therapies for neurodegenerative disease., 1089-8638"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Salameh, Moh'd A. and Robinson, Jessica L. and Navaneetham, Duraiswamy and Sinha, Dipali and Madden, Benjamin J. and Walsh, Peter N. and Radisky, Evette S. (2010) The amyloid precursor protein\/protease nexin 2 {Kunitz} inhibitor domain is a highly specific substrate of mesotrypsin. The Journal of Biological Chemistry 285(3): 1939--1949 https:\/\/doi.org\/10.1074\/jbc.M109.057216, Full Text:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\JXI4S6PN\\\\Salameh et al. - 2010 - The amyloid precursor proteinprotease nexin 2 Kun.pdf:application\/pdf, Animals, Humans, Kinetics, Amino Acid Sequence, Mice, Molecular Sequence Data, Protein Structure, Tertiary, Substrate Specificity, Receptors, Cell Surface, Amyloid beta-Protein Precursor, Cell Line, Tumor, Factor XIa, Protease Inhibitors, Trypsin, Protease Nexins, PMC2804352, 19920152, January, eng, The amyloid precursor protein (APP) is a ubiquitously expressed transmembrane adhesion protein and the progenitor of amyloid-beta peptides. The major splice isoforms of APP expressed by most tissues contain a Kunitz protease inhibitor domain; secreted APP containing this domain is also known as protease nexin 2 and potently inhibits serine proteases, including trypsin and coagulation factors. The atypical human trypsin isoform mesotrypsin is resistant to inhibition by most protein protease inhibitors and cleaves some inhibitors at a substantially accelerated rate. Here, in a proteomic screen to identify potential physiological substrates of mesotrypsin, we find that APP\/protease nexin 2 is selectively cleaved by mesotrypsin within the Kunitz protease inhibitor domain. In studies employing the recombinant Kunitz domain of APP (APPI), we show that mesotrypsin cleaves selectively at the Arg(15)-Ala(16) reactive site bond, with kinetic constants approaching those of other proteases toward highly specific protein substrates. Finally, we show that cleavage of APPI compromises its inhibition of other serine proteases, including cationic trypsin and factor XIa, by 2 orders of magnitude. Because APP\/protease nexin 2 and mesotrypsin are coexpressed in a number of tissues, we suggest that processing by mesotrypsin may ablate the protease inhibitory function of APP\/protease nexin 2 in vivo and may also modulate other activities of APP\/protease nexin 2 that involve the Kunitz domain., 1083-351X","DOI":"10.1074\/jbc.M109.057216"},{"key":"ref4","unstructured":"Jord \u00e0 \u2010Siquier, Tom \u00e0s and Petrel, Melina and Kouskoff, Vladimir and Smailovic, Una and Cordeli \u00e8res, Fabrice and Frykman, Susanne and M \u00fcller, Ulrike and Mulle, Christophe and Barthet, Ga \u00ebl (2022) {APP} accumulates with presynaptic proteins around amyloid plaques: {A} role for presynaptic mechanisms in {Alzheimer}'s disease?. Alzheimer's & Dementia 18(11): 2099--2116 https:\/\/doi.org\/10.1002\/alz.12546, PMC9786597, 35076178, November, 2025-06-12, In Alzheimer's disease (AD), the distribution of the amyloid precursor protein (APP) and its fragments other than amyloid beta, has not been fully characterized. Here, we investigate the distribution of APP and its fragments in human AD brain samples and in mouse models of AD in reference to its proteases, synaptic proteins, and histopathological features characteristic of the AD brain, by combining an extensive set of histological and analytical tools. We report that the prominent somatic distribution of APP observed in control patients remarkably vanishes in human AD patients to the benefit of dense accumulations of extra \u2010somatic APP, which surround dense \u2010core amyloid plaques enriched in APP \u2010Nter. These features are accentuated in patients with familial forms of the disease. Importantly, APP accumulations are enriched in phosphorylated tau and presynaptic proteins whereas they are depleted of post \u2010synaptic proteins suggesting that the extra \u2010somatic accumulations of APP are of presynaptic origin. Ultrastructural analyses unveil that APP concentrates in autophagosomes and in multivesicular bodies together with presynaptic vesicle proteins. Altogether, alteration of APP distribution and its accumulation together with presynaptic proteins around dense \u2010core amyloid plaques is a key histopathological feature in AD, lending support to the notion that presynaptic failure is a strong physiopathological component of AD., https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9786597\/, {APP} accumulates with presynaptic proteins around amyloid plaques, 1552-5260"},{"key":"#cr-split#-ref5.1","doi-asserted-by":"crossref","unstructured":"Evin, Genevi \u00e8ve and Zhu, Aiqin and Holsinger, R.M. Damian and Masters, Colin L. and Li, Qiao-Xin (2003) Proteolytic processing of the {Alzheimer}'s disease amyloid precursor protein in brain and platelets. Journal of Neuroscience Research 74(3): 386--392 https:\/\/doi.org\/10.1002\/jnr.10745, Full Text PDF:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\57IR5G5N\\\\Evin et al. - 2003 - Proteolytic processing of the Alzheimer's disease .pdf:application\/pdf, APP, BACE, presenilin, \u03b3-secretase, \u03f5-cleavage, \\_eprint: https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jnr.10745, 2025-06-04, en, Proteolytic processing of the amyloid precursor protein by \u03b2 -and \u03b3-secretases results in the production of Alzheimer's disease","DOI":"10.1002\/jnr.10745"},{"key":"#cr-split#-ref5.2","unstructured":"(AD) A \u03b2 amyloid peptides. Modulation of secretase activity is being investigated as a potential therapeutic approach. Recent studies with human brain have revealed that the \u03b2-secretase protein, BACE, is increased in cortex of AD patients. Analysis of \u03b2CTF (or C99), the amyloid precursor protein (APP) product of BACE cleavage that is the direct precursor to A \u03b2, shows it is also elevated in AD, underlying the importance of \u03b2-secretase cleavage in AD pathogenesis. The C-terminal product of \u03b3-secretase cleavage of APP, \u03f5CTF (or AICD), is enriched in human brain cortical nuclear fractions, a subcellular distribution appropriate for a putative involvement of APP cytosolic domain in signal transduction. Analysis of AD cortex samples, particularly that of a carrier of a familial APP mutation, suggests that processing of APP transmembrane domain generates an alternative CTF product. All these particularities observed in the AD brain demonstrate that APP processing is altered in AD. The transgenic mouse model Tg2576 seems to be a promising laboratory tool to test potential modulators of A \u03b2 formation. Indeed, C-terminal products of \u03b1-, \u03b2-, and \u03b3-secretase cleavage are readily detectable in the brain of these transgenic mice. Finally, the finding of the same secretase products in platelets and neurons make platelets a potentially useful and easily accessible clinical tool to monitor effects of novel therapies based on inhibition of \u03b2- or \u03b3-secretase. \u00a9 2003 Wiley-Liss, Inc., https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1002\/jnr.10745, 1097-4547, Copyright \u00a9 2003 Wiley-Liss, Inc."},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Hughes, Adam L. and Gottschling, Daniel E. (2012) An early age increase in vacuolar {pH} limits mitochondrial function and lifespan in yeast. Nature 492(7428): 261--265 https:\/\/doi.org\/10.1038\/nature11654, Amino Acids, Gene Expression, Homeostasis, Hydrogen-Ion Concentration, Lysosomes, Microbial Viability, Mitochondria, Proton-Translocating ATPases, Saccharomyces cerevisiae, Saccharomyces cerevisiae Proteins, Vacuoles, PMC3521838, 23172144, December, eng, Mitochondria have a central role in ageing. They are considered to be both a target of the ageing process and a contributor to it. Alterations in mitochondrial structure and function are evident during ageing in most eukaryotes, but how this occurs is poorly understood. Here we identify a functional link between the lysosome-like vacuole and mitochondria in Saccharomyces cerevisiae, and show that mitochondrial dysfunction in replicatively aged yeast arises from altered vacuolar pH. We found that vacuolar acidity declines during the early asymmetric divisions of a mother cell, and that preventing this decline suppresses mitochondrial dysfunction and extends lifespan. Surprisingly, changes in vacuolar pH do not limit mitochondrial function by disrupting vacuolar protein degradation, but rather by reducing pH-dependent amino acid storage in the vacuolar lumen. We also found that calorie restriction promotes lifespan extension at least in part by increasing vacuolar acidity via conserved nutrient-sensing pathways. Interestingly, although vacuolar acidity is reduced in aged mother cells, acidic vacuoles are regenerated in newborn daughters, coinciding with daughter cells having a renewed lifespan potential. Overall, our results identify vacuolar pH as a critical regulator of ageing and mitochondrial function, and outline a potentially conserved mechanism by which calorie restriction delays the ageing process. Because the functions of the vacuole are highly conserved throughout evolution, we propose that lysosomal pH may modulate mitochondrial function and lifespan in other eukaryotic cells., 1476-4687","DOI":"10.1038\/nature11654"},{"key":"ref7","unstructured":"Sun, Yanan and Li, Meijiao and Zhao, Dongfeng and Li, Xin and Yang, Chonglin and Wang, Xiaochen (2020) Lysosome activity is modulated by multiple longevity pathways and is important for lifespan extension in {C}. elegans. eLife 9: e55745 https:\/\/doi.org\/10.7554\/eLife.55745, Full Text:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\3W3B4W55\\\\Sun et al. - 2020 - Lysosome activity is modulated by multiple longevi.pdf:application\/pdf, aging, Animals, C. elegans, Caenorhabditis elegans, Caenorhabditis elegans Proteins, cell biology, DAF-16\/FOXO, insuin\/igf-1 signaling, Insulin, Insulin-Like Growth Factor I, Longevity, longevity pathways, lysosome, Lysosomes, Receptor, Insulin, Signal Transduction, SKN-1\/NRF2, PMC7274789, 32482227, June, eng, Lysosomes play important roles in cellular degradation to maintain cell homeostasis. In order to understand whether and how lysosomes alter with age and contribute to lifespan regulation, we characterized multiple properties of lysosomes during the aging process in C. elegans. We uncovered age-dependent alterations in lysosomal morphology, motility, acidity and degradation activity, all of which indicate a decline in lysosome function with age. The age-associated lysosomal changes are suppressed in the long-lived mutants daf-2, eat-2 and isp-1, which extend lifespan by inhibiting insulin\/IGF-1 signaling, reducing food intake and impairing mitochondrial function, respectively. We found that 43 lysosome genes exhibit reduced expression with age, including genes encoding subunits of the proton pump V-ATPase and cathepsin proteases. The expression of lysosome genes is upregulated in the long-lived mutants, and this upregulation requires the functions of DAF-16\/FOXO and SKN-1\/NRF2 transcription factors. Impairing lysosome function affects clearance of aggregate-prone proteins and disrupts lifespan extension in daf-2, eat-2 and isp-1 worms. Our data indicate that lysosome function is modulated by multiple longevity pathways and is important for lifespan extension., 2050-084X"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Aow, Jonathan and Huang, Tzu-Rung and Goh, Yeek Teck and Sun, Alfred Xuyang and Thinakaran, Gopal and Koo, Edward H. (2023) Evidence for a clathrin-independent endocytic pathway for {APP} internalization in the neuronal somatodendritic compartment. Cell Reports 42(7): 112774 https:\/\/doi.org\/10.1016\/j.celrep.2023.112774, Aow et al. - 2023 - Evidence for a clathrin-independent endocytic path.pdf:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\IVCRJPNC\\\\Aow et al. - 2023 - Evidence for a clathrin-independent endocytic path.pdf:application\/pdf;Full Text:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\747YRTN5\\\\Aow et al. - 2023 - Evidence for a clathrin-independent endocytic path.pdf:application\/pdf, Humans, Neurons, Alzheimer Disease, Amyloid beta-Protein Precursor, Amyloid Precursor Protein Secretases, A \u03b2, amyloid precursor protein, APP, Amyloid beta-Peptides, amyloid-beta, Bace1, Clathrin, clathrin motif, CP: Cell biology, CP: Neuroscience, dynamin, Dynamins, Endocytosis, internalization, somatodendritic compartment,  \u03b2-secretase, PMC10449584, 37450368, July, eng, Amyloid precursor protein (APP) internalization via clathrin-\/dynamin-mediated endocytosis (CME) mediated by its YENPTY motif into endosomes containing  \u03b2-secretase is proposed to be critical for amyloid-beta (A \u03b2) production. Here, we show that somatodendritic APP internalization in primary rodent neurons is not blocked by inhibiting dynamin or mutating the YENPTY motif, in contrast to non-neuronal cell lines. These phenomena, confirmed in induced human neurons under dynamin inhibition, occur during basal conditions and chemical long-term-depression stimulus, pointing to a clathrin-independent internalization pathway for somatodendritic APP. Mutating the YENPTY motif does not alter APP recycling, degradation, or endolysosomal colocalization. However, both dynamin inhibition and the YENPTY mutant significantly decrease secreted A \u03b2 in neurons, suggesting that internalized somatodendritic APP may not constitute a major source of A \u03b2. Interestingly, like APP, somatodendritic low-density lipoprotein receptor (LDLR) internalization does not require its CME motif. These results highlight intriguing differences in neuronal internalization pathways and refine our understanding of A \u03b2 production and secretion., 2211-1247","DOI":"10.1016\/j.celrep.2023.112774"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Sampognaro, Paul J. and Arya, Shruti and Knudsen, Giselle M. and Gunderson, Emma L. and Sandoval-Perez, Angelica and Hodul, Molly and Bowles, Katherine and Craik, Charles S. and Jacobson, Matthew P. and Kao, Aimee W. (2023) Mutations in $$\\alpha$$-synuclein, {TDP}-43 and tau prolong protein half-life through diminished degradation by lysosomal proteases. Molecular Neurodegeneration 18(1): 29 https:\/\/doi.org\/10.1186\/s13024-023-00621-8, 13024_2023_621_MOESM1_ESM.pdf:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\EA94HLTW\\\\13024_2023_621_MOESM1_ESM.pdf:application\/pdf;Full Text PDF:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\BU3ERQL6\\\\Sampognaro et al. - 2023 - Mutations in $\\alpha$-synuclein, TDP-43 and tau prolong p.pdf:application\/pdf;Snapshot:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\AQBBPSHL\\\\s13024-023-00621-8.html:text\/html, Autophagy, Cathepsin, Lysosome, Mutations, Neurodegeneration, Protease, Tau, TDP-43, $\\alpha$-synuclein, May, 2023-05-25, Autosomal dominant mutations in $\\alpha$-synuclein, TDP-43 and tau are thought to predispose to neurodegeneration by enhancing protein aggregation. While a subset of $\\alpha$-synuclein, TDP-43 and tau mutations has been shown to increase the structural propensity of these proteins toward self-association, rates of aggregation are also highly dependent on protein steady state concentrations, which are in large part regulated by their rates of lysosomal degradation. Previous studies have shown that lysosomal proteases operate precisely and not indiscriminately, cleaving their substrates at very specific linear amino acid sequences. With this knowledge, we hypothesized that certain coding mutations in $\\alpha$-synuclein, TDP-43 and tau may lead to increased protein steady state concentrations and eventual aggregation by an alternative mechanism, that is, through disrupting lysosomal protease cleavage recognition motifs and subsequently conferring protease resistance to these proteins., https:\/\/doi.org\/10.1186\/s13024-023-00621-8, 1750-1326","DOI":"10.1186\/s13024-023-00621-8"},{"key":"ref10","unstructured":"Lee, Ju-Hyun and Nixon, Ralph A. (2022) Autolysosomal acidification failure as a primary driver of {Alzheimer} disease pathogenesis. Autophagy 18(11): 2763--2764 https:\/\/doi.org\/10.1080\/15548627.2022.2110729, Full Text PDF:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\SN6DNTWX\\\\Lee and Nixon - 2022 - Autolysosomal acidification failure as a primary d.pdf:application\/pdf, Alzheimer \u2019s disease, Amyloid plaque, Autophagy, A$$\\beta$$\/APP-$\\beta$CTF, lysosome acidification, Perikaryal blebbing, Publisher: Taylor \\& Francis\\_eprint: https:\/\/doi.org\/10.1080\/15548627.2022.2110729, 35947489, November, 2023-08-04, Genetic evidence has increasingly linked lysosome dysfunction to an impaired autophagy-lysosomal pathway (ALP) flux in Alzheimer disease (AD) although the relationship of these abnormalities to other pathologies is unclear. In our recent investigation on the origin of impaired autophagic flux in AD, we established the critical early role of defective lysosomes in five mouse AD models. To assess in vivo alterations of autophagy and ALP vesicle acidification, we expressed eGFP-mRFP-LC3 specifically in neurons. We discovered that autophagy dysfunction in these models arises from exceptionally early failure of autolysosome\/lysosome acidification, which then drives downstream AD pathogenesis. Extreme autophagic stress in compromised but still intact neurons causes autophagic vacuoles (AVs) containing toxic APP metabolites, A$\\beta$\/$\\beta$-CTFs, to pack into huge blebs and protrude from the perikaryon membrane. Most notably, AVs also coalesce with ER tubules and yield fibrillar $\\beta$-amyloid within these tubules. Collectively, amyloid immunoreactivity within these intact neurons assumes the appearance of amyloid-plaques, and indeed, their eventual death transforms them into extracellular plaque lesions. Quantitative analysis confirms that neurons undergoing this transformation are the principal source of $\\beta$-amyloid-plaques in APP-AD models. These findings prompt reconsideration of the conventionally accepted sequence of events in plaque formation and may help explain the inefficacy of A$\\beta$\/amyloid vaccine therapies., https:\/\/doi.org\/10.1080\/15548627.2022.2110729, 1554-8627"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Lee, Ju-Hyun and Yang, Dun-Sheng and Goulbourne, Chris N. and Im, Eunju and Stavrides, Philip and Pensalfini, Anna and Chan, Han and Bouchet-Marquis, Cedric and Bleiwas, Cynthia and Berg, Martin J. and Huo, Chunfeng and Peddy, James and Pawlik, Monika and Levy, Efrat and Rao, Mala and Staufenbiel, Mathias and Nixon, Ralph A. (2022) Faulty autolysosome acidification in {Alzheimer} \u2019s disease mouse models induces autophagic build-up of {A$$\\beta$$} in neurons, yielding senile plaques. Nature Neuroscience 25(6): 688--701 https:\/\/doi.org\/10.1038\/s41593-022-01084-8, Full Text PDF:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\NW9PEJ3G\\\\Lee et al. - 2022 - Faulty autolysosome acidification in Alzheimer\u2019s d.pdf:application\/pdf, Alzheimer's disease, Autophagy, Cellular neuroscience, Lysosomes, Number: 6Publisher: Nature Publishing Group, June, 2023-08-04, en, Autophagy is markedly impaired in Alzheimer\u2019s disease (AD). Here we reveal unique autophagy dysregulation within neurons in five AD mouse models in vivo and identify its basis using a neuron-specific transgenic mRFP-eGFP-LC3 probe of autophagy and pH, multiplex confocal imaging and correlative light electron microscopy. Autolysosome acidification declines in neurons well before extracellular amyloid deposition, associated with markedly lowered vATPase activity and build-up of A$\\beta$\/APP-$\\beta$CTF selectively within enlarged de-acidified autolysosomes. In more compromised yet still intact neurons, profuse A$\\beta$-positive autophagic vacuoles (AVs) pack into large membrane blebs forming flower-like perikaryal rosettes. This unique pattern, termed PANTHOS (poisonous anthos (flower)), is also present in AD brains. Additional AVs coalesce into peri-nuclear networks of membrane tubules where fibrillar $\\beta$-amyloid accumulates intraluminally. Lysosomal membrane permeabilization, cathepsin release and lysosomal cell death ensue, accompanied by microglial invasion. Quantitative analyses confirm that individual neurons exhibiting PANTHOS are the principal source of senile plaques in amyloid precursor protein AD models., https:\/\/www.nature.com\/articles\/s41593-022-01084-8, 1546-1726, 2022 The Author(s)","DOI":"10.1038\/s41593-022-01084-8"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Hampel, Harald and Hardy, John and Blennow, Kaj and Chen, Christopher and Perry, George and Kim, Seung Hyun and Villemagne, Victor L. and Aisen, Paul and Vendruscolo, Michele and Iwatsubo, Takeshi and Masters, Colin L. and Cho, Min and Lannfelt, Lars and Cummings, Jeffrey L. and Vergallo, Andrea (2021) The {Amyloid}-$$\\beta$$ {Pathway} in {Alzheimer}'s {Disease}. Molecular Psychiatry 26(10): 5481--5503 https:\/\/doi.org\/10.1038\/s41380-021-01249-0, Full Text:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\F6HGVCUT\\\\Hampel et al. - 2021 - The Amyloid-$\\beta$ Pathway in Alzheimer's Disease.pdf:application\/pdf, Alzheimer Disease, Amyloid beta-Peptides, Biomarkers, Humans, tau Proteins, PMC8758495, 34456336, October, eng, Breakthroughs in molecular medicine have positioned the amyloid-$\\beta$ (A$\\beta$) pathway at the center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular mechanisms of the pathway and the spatial-temporal dynamics leading to synaptic failure, neurodegeneration, and clinical onset are still under intense investigation, the established biochemical alterations of the A$\\beta$ cycle remain the core biological hallmark of AD and are promising targets for the development of disease-modifying therapies. Here, we systematically review and update the vast state-of-the-art literature of A$\\beta$ science with evidence from basic research studies to human genetic and multi-modal biomarker investigations, which supports a crucial role of A$\\beta$ pathway dyshomeostasis in AD pathophysiological dynamics. We discuss the evidence highlighting a differentiated interaction of distinct A$\\beta$ species with other AD-related biological mechanisms, such as tau-mediated, neuroimmune and inflammatory changes, as well as a neurochemical imbalance. Through the lens of the latest development of multimodal in vivo biomarkers of AD, this cross-disciplinary review examines the compelling hypothesis- and data-driven rationale for A$\\beta$-targeting therapeutic strategies in development for the early treatment of AD., 1476-5578","DOI":"10.1038\/s41380-021-01249-0"},{"key":"ref13","unstructured":"Yadati, Tulasi and Houben, Tom and Bitorina, Albert and Shiri-Sverdlov, Ronit (2020) The {Ins} and {Outs} of {Cathepsins}: {Physiological} {Function} and {Role} in {Disease} {Management}. Cells 9(7): 1679 https:\/\/doi.org\/10.3390\/cells9071679, Full Text PDF:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\5D3SBJ6Z\\\\Yadati et al. - 2020 - The Ins and Outs of Cathepsins Physiological Func.pdf:application\/pdf, PMC7407943, 32668602, July, 2023-08-07, Cathepsins are the most abundant lysosomal proteases that are mainly found in acidic endo\/lysosomal compartments where they play a vital role in intracellular protein degradation, energy metabolism, and immune responses among a host of other functions. The discovery that cathepsins are secreted and remain functionally active outside of the lysosome has caused a paradigm shift. Contemporary research has unraveled many versatile functions of cathepsins in extralysosomal locations including cytosol and extracellular space. Nevertheless, extracellular cathepsins are majorly upregulated in pathological states and are implicated in a wide range of diseases including cancer and cardiovascular diseases. Taking advantage of the differential expression of the cathepsins during pathological conditions, much research is focused on using cathepsins as diagnostic markers and therapeutic targets. A tailored therapeutic approach using selective cathepsin inhibitors is constantly emerging to be safe and efficient. Moreover, recent development of proteomic-based approaches for the identification of novel physiological substrates offers a major opportunity to understand the mechanism of cathepsin action. In this review, we summarize the available evidence regarding the role of cathepsins in health and disease, discuss their potential as biomarkers of disease progression, and shed light on the potential of extracellular cathepsin inhibitors as safe therapeutic tools., https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7407943\/, The {Ins} and {Outs} of {Cathepsins}, 2073-4409"},{"key":"ref14","unstructured":"Root, Jessica and Merino, Paola and Nuckols, Austin and Johnson, Michelle and Kukar, Thomas (2021) Lysosome dysfunction as a cause of neurodegenerative diseases: {Lessons} from frontotemporal dementia and amyotrophic lateral sclerosis. Neurobiology of Disease 154: 105360 https:\/\/doi.org\/10.1016\/j.nbd.2021.105360, Accepted Version:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\AI2IHMDC\\\\Root et al. - 2021 - Lysosome dysfunction as a cause of neurodegenerati.pdf:application\/pdf;Root et al. - 2021 - Lysosome dysfunction as a cause of neurodegenerati.pdf:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\Z3EGXKIC\\\\Root et al. - 2021 - Lysosome dysfunction as a cause of neurodegenerati.pdf:application\/pdf, Alzheimer's disease and related dementias (ADRD), Amyotrophic Lateral Sclerosis, Amyotrophic lateral sclerosis (ALS), Animals, Autophagy, C9orf72, Frontotemporal Dementia, Frontotemporal dementia (FTD), Frontotemporal lobar degeneration (FTLD), Granulins (GRNs), Humans, Lysosome dysfunction, Lysosomes, Microtubule-associated protein tau (MAPT), Nerve Tissue Proteins, Neurodegeneration, Neurodegenerative Diseases, Progranulin (PGRN), Transactive response DNA binding protein 43 \u00a0kDa (TDP-43), Transcription factor EB (TFEB), Transmembrane protein 106B (TMEM106B), Ubiquitin, PMC8113138, 33812000, July, eng, Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum. FTD and ALS are linked by shared genetic causes (e.g. C9orf72 hexanucleotide repeat expansions) and neuropathology, such as inclusions of ubiquitinated, misfolded proteins (e.g. TAR DNA-binding protein 43; TDP-43) in the CNS. Furthermore, some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function, including lysosomal fusion, cargo trafficking, lysosomal acidification, autophagy, or TFEB activity. In this review, we summarize evidence that lysosomal dysfunction, caused by genetic mutations (e.g. C9orf72, GRN, MAPT, TMEM106B) or toxic-gain of function (e.g. aggregation of TDP-43 or tau), is an important pathogenic disease mechanism in FTD and ALS. Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS. Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases, including Alzheimer's (e.g. APOE, PSEN1, APP) and Parkinson's (e.g. GBA, LRRK2, ATP13A2) disease. A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases., Lysosome dysfunction as a cause of neurodegenerative diseases, 1095-953X"},{"key":"ref15","unstructured":"O \u2019Brien, Richard J. and Wong, Philip C. (2011) Amyloid {Precursor} {Protein} {Processing} and {Alzheimer} \u2019s {Disease}. Annual review of neuroscience 34: 185--204 https:\/\/doi.org\/10.1146\/annurev-neuro-061010-113613, PubMed Central Full Text PDF:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\L6L8JQTB\\\\O \u2019Brien and Wong - 2011 - Amyloid Precursor Protein Processing and Alzheimer.pdf:application\/pdf, PMC3174086, 21456963, 2023-08-08, Alzheimer \u2019s disease (AD), the leading cause of dementia worldwide, is characterized by the accumulation of the $$\\beta$$-amyloid peptide (A$\\beta$) within the brain along with hyperphosphorylated and cleaved forms of the microtubule-associated protein tau. Genetic, biochemical, and behavioral research suggest that physiologic generation of the neurotoxic A$\\beta$ peptide from sequential amyloid precursor protein (APP) proteolysis is the crucial step in the development of AD. APP is a single-pass transmembrane protein expressed at high levels in the brain and metabolized in a rapid and highly complex fashion by a series of sequential proteases, including the intramembranous $$\\gamma$$-secretase complex, which also process other key regulatory molecules. Why A$\\beta$ accumulates in the brains of elderly individuals is unclear but could relate to changes in APP metabolism or A$\\beta$ elimination. Lessons learned from biochemical and genetic studies of APP processing will be crucial to the development of therapeutic targets to treat AD., https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3174086\/, 0147-006X"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Jonsson, Thorlakur and Atwal, Jasvinder K. and Steinberg, Stacy and Snaedal, Jon and Jonsson, Palmi V. and Bjornsson, Sigurbjorn and Stefansson, Hreinn and Sulem, Patrick and Gudbjartsson, Daniel and Maloney, Janice and Hoyte, Kwame and Gustafson, Amy and Liu, Yichin and Lu, Yanmei and Bhangale, Tushar and Graham, Robert R. and Huttenlocher, Johanna and Bjornsdottir, Gyda and Andreassen, Ole A. and J \u00f6nsson, Erik G. and Palotie, Aarno and Behrens, Timothy W. and Magnusson, Olafur T. and Kong, Augustine and Thorsteinsdottir, Unnur and Watts, Ryan J. and Stefansson, Kari (2012) A mutation in {APP} protects against {Alzheimer} \u2019s disease and age-related cognitive decline. Nature 488(7409): 96--99 https:\/\/doi.org\/10.1038\/nature11283, Full Text PDF:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\46VQG6QG\\\\Jonsson et al. - 2012 - A mutation in APP protects against Alzheimer \u2019s dis.pdf:application\/pdf, Alzheimer's disease, Disease genetics, Genetic variation, Number: 7409 Publisher: Nature Publishing Group, August, 2023-08-08, en, A coding mutation in APP, the gene that encodes the amyloid-$$\\beta$$ precursor protein, is found to protect against Alzheimer\u2019s disease and cognitive decline in the elderly without Alzheimer\u2019s disease., https:\/\/www.nature.com\/articles\/nature11283, 1476-4687, 2012 Springer Nature Limited","DOI":"10.1038\/nature11283"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Hung, Christy O.Y. and Livesey, Frederick J. (2018) Altered $$\\gamma$$-{Secretase} {Processing} of {APP} {Disrupts} {Lysosome} and {Autophagosome} {Function} in {Monogenic} {Alzheimer}\u2019s {Disease}. Cell Reports 25(13): 3647--3660.e2 https:\/\/doi.org\/10.1016\/j.celrep.2018.11.095, Hung and Livesey - 2018 - Altered $\\gamma$-Secretase Processing of APP Disrupts Lys.pdf:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\IDERZDCZ\\\\Hung and Livesey - 2018 - Altered $\\gamma$-Secretase Processing of APP Disrupts Lys.pdf:application\/pdf, December, 2023-08-09, en, Abnormalities of the endolysosomal and autophagy systems are found in Alzheimer\u2019s disease, but it is not clear whether defects in these systems are a cause or consequence of degenerative processes in the disease. In human neuronal models of monogenic Alzheimer\u2019s disease, APP and PSEN1 mutations disrupt lysosome function and autophagy, leading to impaired lysosomal proteolysis and defective autophagosome clearance. Processing of APP by g-secretase is central to the pathogenic changes in the lysosome-autophagy system caused by PSEN1 and APP mutations: reducing production of C-terminal APP by inhibition of BACE1 rescued these phenotypes in both APP and PSEN1 mutant neurons, whereas inhibition of g-secretase induced lysosomal and autophagic pathology in healthy neurons. Defects in lysosomes and autophagy due to PSEN1 mutations are rescued by CRISPR-knockout of APP. These data demonstrate a key role for proteolysis of the C-terminal of APP by g-secretase in neuronal dysfunction in monogenic Alzheimer\u2019s disease., https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211124718318862, 22111247","DOI":"10.1016\/j.celrep.2018.11.095"},{"key":"ref18","unstructured":"Nixon, Ralph A. (2017) Amyloid precursor protein and endosomal \u2010lysosomal dysfunction in {Alzheimer}'s disease: inseparable partners in a multifactorial disease. The FASEB Journal 31(7): 2729--2743 https:\/\/doi.org\/10.1096\/fj.201700359, Full Text PDF:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\QRNSN2IQ\\\\Nixon - 2017 - Amyloid precursor protein and endosomal-lysosomal .pdf:application\/pdf;Nixon - 2017 - Amyloid precursor protein and endosomal \u2010lysosomal .pdf:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\7T2C2L5B\\\\Nixon - 2017 - Amyloid precursor protein and endosomal \u2010lysosomal .pdf:application\/pdf;Snapshot:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\4EUFRCE8\\\\fj.html:text\/html, apoliprotein E, autophagy, cholinergic neurodegeneration, Down Syndrome, presenilin, July, 2023-08-09, en, Abnormalities of the endosomal-lysosomal network (ELN) are a signature feature of Alzheimer's disease (AD). These include the earliest known cytopathology that is specific to AD and that affects endosomes and induces the progressive failure of lysosomes, each of which are directly linked by distinct mechanisms to neurodegeneration. Th origins of ELN dysfunction and $$\\beta$$-amyloidogenesis closely overlap, which reflects their common genetic basis, the established early involvement of endosomes and lysosomes in amyloid precursor protein (APP) processing and clearance, and the pathologic effect of certain APP metabolites on ELN functions. Genes that promote $\\beta$amyloidogenesis in AD (APP, PSEN1\/2, and APOE4) have primary effects on ELN function. The importance of primary ELN dysfunction to pathogenesis is underscored by the mutations in more than 35 ELN-related genes that, thus far, are known to cause familial neurodegenerative diseases even though different pathogenic proteins may be involved In this article, I discuss growing evidence that implicates AD gene-driven ELN disruptions as not only the antecedent pathobiology that underlies $\\beta$-amyloidogenesis but also as the essential partner with APP and its metabolites that drive the development of AD, including tauopathy, synaptic dysfunction, and neurodegeneration. The striking amelioration of diverse deficits in animal AD models by remediating ELN dysfunction further supports a need to integrate APP and ELN relationships, including the role of amyloid-$\\beta$, into a broader conceptual framework of how A arises, progresses, and may be effectively therapeutically targeted.-Nixon, R. A. Amyloid precursor protein and endosomal-lysosomal dysfunction in Alzheimer's disease: inseparable partners in a multifactorial disease., https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1096\/fj.201700359, Amyloid precursor protein and endosomal\u2010lysosomal dysfunction in {Alzheimer}'s disease, 0892-6638, 1530-6860"},{"key":"ref19","unstructured":"Zhang, Yun-wu and Thompson, Robert and Zhang, Han and Xu, Huaxi (2011) {APP} processing in {Alzheimer}'s disease. Molecular Brain 4(1): 3 https:\/\/doi.org\/10.1186\/1756-6606-4-3, Zhang et al. - 2011 - APP processing in Alzheimer's disease.pdf:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\WLQK9GPI\\\\Zhang et al. - 2011 - APP processing in Alzheimer's disease.pdf:application\/pdf, 2023-08-09, en, An important pathological feature of Alzheimer \u2019s disease (AD) is the presence of extracellular senile plaques in the brain. Senile plaques are composed of aggregations of small peptides called b-amyloid (Ab). Multiple lines of evidence demonstrate that overproduction\/aggregation of Ab in the brain is a primary cause of AD and inhibition of Ab generation has become a hot topic in AD research. Ab is generated from b-amyloid precursor protein (APP) through sequential cleavages first by b-secretase and then by g-secretase complex. Alternatively, APP can be cleaved by a-secretase within the Ab domain to release soluble APPa and preclude Ab generation. Cleavage of APP by caspases may also contribute to AD pathologies. Therefore, understanding the metabolism\/processing of APP is crucial for AD therapeutics. Here we review current knowledge of APP processing regulation as well as the patho\/physiological functions of APP and its metabolites., http:\/\/molecularbrain.biomedcentral.com\/articles\/10.1186\/1756-6606-4-3, 1756-6606"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Nixon, Ralph A. (2020) The aging lysosome: {An} essential catalyst for late-onset neurodegenerative diseases. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 1868(9): 140443 https:\/\/doi.org\/10.1016\/j.bbapap.2020.140443, Nixon - 2020 - The aging lysosome An essential catalyst for late.pdf:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\WP3RFSUN\\\\Nixon - 2020 - The aging lysosome An essential catalyst for late.pdf:application\/pdf, September, 2023-08-11, en, Lysosomes figure prominently in theories of aging as the proteolytic system most responsible for eliminating growing burdens of damaged proteins and organelles in aging neurons and other long lived cells. Newer evidence shows that diverse experimental measures known to extend lifespan in invertebrate aging models share the property of boosting lysosomal clearance of substrates through the autophagy pathway. Maintaining an optimal level of lysosome acidification is particularly crucial for these anti-aging effects. The exceptional dependence of neurons on fully functional lysosomes is reflected by the neurological phenotypes that develop in congenital lysosomal storage disorders, which commonly present as severe neurodevelopmental or neurodegenerative conditions even though the lysosomal deficit maybe systemic. Similar connections are now being appreciated between primary lysosomal deficit and the risk for late age-onset neurodegenerative disorders. In diseases such as Alzheimer's and Parkinson's, as in aging alone, primary lysosome dysfunction due to acidification impairment is emerging as a frequent theme, supported by the growing list of familial neurodegenerative disorders that involve primary vATPase dysfunction. The additional cellular roles played by intraluminal pH in sensing nutrient and stress and modulating cellular signaling have further expanded the possible ways that lysosomal pH dysregulation in aging and disease can disrupt neuronal function. Here, we consider the impact of cellular aging on lysosomes and how the changes during aging may create the tipping point for disease emergence in major late-age onset neurodegenerative disorders., https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S157096392030090X, The aging lysosome, 15709639","DOI":"10.1016\/j.bbapap.2020.140443"},{"key":"ref21","unstructured":"Kimura, Ayano and Hata, Saori and Suzuki, Toshiharu (2016) Alternative {Selection} of $$\\beta$$-{Site} {APP}-{Cleaving} {Enzyme} 1 ({BACE1}) {Cleavage} {Sites} in {Amyloid} $\\beta$-{Protein} {Precursor} ({APP}) {Harboring} {Protective} and {Pathogenic} {Mutations} within the {A$\\beta$} {Sequence}*. Journal of Biological Chemistry 291(46): 24041--24053 https:\/\/doi.org\/10.1074\/jbc.M116.744722, ScienceDirect Full Text PDF:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\WVJG2AQU\\\\Kimura et al. - 2016 - Alternative Selection of $\\beta$-Site APP-Cleaving Enzym.pdf:application\/pdf;ScienceDirect Snapshot:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\4D943BWU\\\\S0021925820346743.html:text\/html, Alzheimer disease, amyloid precursor protein (APP), amyloid-$\\beta$ (A$\\beta$), secretase, $\\beta$-secretase 1 (BACE1), November, 2023-08-17, $\\beta$-Site APP-cleaving enzyme 1 (BACE1) cleaves amyloid $\\beta$-protein precursor (APP) at the bond between Met671 and Asp672 ($\\beta$-site) to generate the carboxyl-terminal fragment (CTF$\\beta$\/C99). BACE1 also cleaves APP at another bond between Thr681 and Gln682 ($\\beta$\u2032-site), yielding CTF$\\beta$\u2032\/C89. Cleavage of CTF$\\beta$\/C99 by $$\\gamma$$-secretase generates A$\\beta$(1-XX), whereas cleavage of CTF$\\beta$\u2032\/C89 generates A$\\beta$(11-XX). Thus, $\\beta$\u2032-site cleavage by BACE1 is amyloidolytic rather than amyloidogenic. $\\beta$\u2032 cleavage of mouse APP is more common than the corresponding cleavage of human APP. We found that the H684R substitution within human A$\\beta$, which replaces the histidine in the human protein with the arginine found at the corresponding position in mouse, facilitated $\\beta$\u2032 cleavage irrespective of the species origin of BACE1, thereby significantly increasing the level of A$\\beta$(11-XX) and decreasing the level of A$\\beta$(1-XX). Thus, amino acid substitutions within the A$\\beta$ sequence influenced the selectivity of alternative $\\beta$- or $\\beta$\u2032-site cleavage of APP by BACE1. In familial Alzheimer's disease (FAD), the APP gene harbors pathogenic variations such as the Swedish (K670N\/M671L), Leuven (E682K), and A673V mutations, all of which decrease A$\\beta$(11\u201340) generation, whereas the protective Icelandic mutation (A673T) increases generation of A$\\beta$(11\u201340). Thus, A673T promotes $\\beta$\u2032 cleavage of APP and protects subjects against AD. In addition, CTF$\\beta$\/C99 was cleaved by excess BACE1 activity to generate CTF$\\beta$\u2032\/C89, followed by A$\\beta$(11\u201340), even if APP harbored pathogenic mutations. The resultant A$\\beta$(11\u201340) was more metabolically labile in vivo than A$\\beta$(1\u201340). Our analysis suggests that some FAD mutations in APP are amyloidogenic and\/or amyloidolytic via selection of alternative BACE1 cleavage sites., https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0021925820346743, 0021-9258"},{"key":"ref22","unstructured":"Park, Hankum and Hundley, Frances V. and Yu, Qing and Overmyer, Katherine A. and Brademan, Dain R. and Serrano, Lia and Paulo, Joao A. and Paoli, Julia C. and Swarup, Sharan and Coon, Joshua J. and Gygi, Steven P. and Wade Harper, J. (2022) Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics. Nature Communications 13(1): 6112 https:\/\/doi.org\/10.1038\/s41467-022-33881-x, 41467_2022_33881_MOESM1_ESM.pdf:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\D25XV4BX\\\\41467_2022_33881_MOESM1_ESM.pdf:application\/pdf;Full Text PDF:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\THBDNIXL\\\\Park et al. - 2022 - Spatial snapshots of amyloid precursor protein int.pdf:application\/pdf, Endosomes, Isolation, Lysosomes, Mass spectrometry, separation and purification, Number: 1 Publisher: Nature Publishing Group, October, 2023-08-23, en, Degradation and recycling of plasma membrane proteins occurs via the endolysosomal system, wherein endosomes bud into the cytosol from the plasma membrane and subsequently mature into degradative lysosomal compartments. While methods have been developed for rapid selective capture of lysosomes (Lyso-IP), analogous methods for isolation of early endosome intermediates are lacking. Here, we develop an approach for rapid isolation of early\/sorting endosomes through affinity capture of the early endosome-associated protein EEA1 (Endo-IP) and provide proteomic and lipidomic snapshots of EEA1-positive endosomes in action. We identify recycling, regulatory and membrane fusion complexes, as well as candidate cargo, providing a proteomic landscape of early\/sorting endosomes. To demonstrate the utility of the method, we combined Endo- and Lyso-IP with multiplexed targeted proteomics to provide a spatial digital snapshot of amyloid precursor protein (APP) processing by $$\\beta$$ and $$\\gamma$$-Secretases, which produce amyloidogenic A$\\beta$ species, and quantify small molecule modulation of Secretase action on endosomes. We anticipate that the Endo-IP approach will facilitate systematic interrogation of processes that are coordinated on EEA1-positive endosomes., https:\/\/www.nature.com\/articles\/s41467-022-33881-x, 2041-1723, 2022 The Author(s)"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Garc \u00eda-Gonz \u00e1lez, Laura and Pilat, Dominika and Baranger, K \u00e9vin and Rivera, Santiago (2019) Emerging {Alternative} {Proteinases} in {APP} {Metabolism} and {Alzheimer} \u2019s {Disease} {Pathogenesis}: {A} {Focus} on {MT1}-{MMP} and {MT5}-{MMP}. Frontiers in Aging Neuroscience 11Full Text PDF:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\E6KSJUEZ\\\\Garc \u00eda-Gonz \u00e1lez et al. - 2019 - Emerging Alternative Proteinases in APP Metabolism.pdf:application\/pdf, 2023-09-09, Processing of amyloid beta precursor protein (APP) into amyloid-beta peptide (A$$\\beta$$) by $\\beta$-secretase and $$\\gamma$$-secretase complex is at the heart of the pathogenesis of Alzheimer\u2019s disease (AD). Targeting this proteolytic pathway effectively reduces\/prevents pathology and cognitive decline in preclinical experimental models of the disease, but therapeutic strategies based on secretase activity modifying drugs have so far failed in clinical trials. Although this may raise some doubts on the relevance of $\\beta$- and $\\gamma$-secretases as targets, new APP-cleaving enzymes, including meprin-$\\beta$, legumain (\u03b4-secretase), rhomboid-like protein-4 (RHBDL4), caspases and membrane-type matrix metalloproteinases (MT-MMPs\/\u03b7-secretases) have confirmed that APP processing remains a solid mechanism in AD pathophysiology. This review will discuss recent findings on the roles of all these proteinases in the nervous system, and in particular on the roles of MT-MMPs, which are at the crossroads of pathological events involving not only amyloidogenesis, but also inflammation and synaptic dysfunctions. Assessing the potential of these emerging proteinases in the Alzheimer\u2019s field opens up new research prospects to improve our knowledge of fundamental mechanisms of the disease and help us establish new therapeutic strategies., https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2019.00244, Emerging {Alternative} {Proteinases} in {APP} {Metabolism} and {Alzheimer}\u2019s {Disease} {Pathogenesis}, 1663-4365","DOI":"10.3389\/fnagi.2019.00244"},{"key":"ref24","unstructured":"Toh, Wei Hong and Tan, Jing Zhi A. and Zulkefli, Khalisah L. and Houghton, Fiona J. and Gleeson, Paul A. (2017) Amyloid precursor protein traffics from the {Golgi} directly to early endosomes in an {Arl5b}- and {AP4}-dependent pathway. Traffic 18(3): 159--175 https:\/\/doi.org\/10.1111\/tra.12465, Full Text PDF:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\6WHSPA7D\\\\Toh et al. - 2017 - Amyloid precursor protein traffics from the Golgi .pdf:application\/pdf;Snapshot:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\7IX659QJ\\\\tra.html:text\/html, amyloid precursor protein, amyloid-$$\\beta$$ peptide, anterograde transport, AP4, Arl5b, early endosomes, trans-Golgi network, \\_eprint: https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tra.12465, 2023-09-10, en, The intracellular trafficking and proteolytic processing of the membrane-bound amyloid precursor protein (APP) are coordinated events leading to the generation of pathogenic amyloid-beta (A$\\beta$) peptides. The membrane transport of newly synthesized APP from the Golgi to the endolysosomal system is not well defined, yet it is likely to be critical for regulating its processing by $\\beta$-secretase (BACE1) and $$\\gamma$$-secretase. Here, we show that the majority of newly synthesized APP is transported from the trans-Golgi network (TGN) directly to early endosomes and then subsequently to the late endosomes\/lysosomes with very little transported to the cell surface. We show that Arl5b, a small G protein localized to the TGN, and AP4 are essential for the post-Golgi transport of APP to early endosomes. Arl5b is physically associated with AP4 and is required for the recruitment of AP4, but not AP1, to the TGN. Depletion of either Arl5b or AP4 results in the accumulation of APP, but not BACE1, in the Golgi, and an increase in APP processing and A$\\beta$ secretion. These findings demonstrate that APP is diverted from BACE1 at the TGN for direct transport to early endosomes and that the TGN represents a site for APP processing with the subsequent secretion of A$\\beta$., https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111\/tra.12465, 1600-0854, \u00a9 2016 John Wiley \\& Sons A\/S. Published by John Wiley \\& Sons Ltd"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Kepp, Kasper P and Robakis, Nikolaos K and H \u00f8ilund-Carlsen, Poul F and Sensi, Stefano L and Vissel, Bryce (2023) The amyloid cascade hypothesis: an updated critical review. Brain : awad159 https:\/\/doi.org\/10.1093\/brain\/awad159, Full Text PDF:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\DC7Q8NTV\\\\Kepp et al. - 2023 - The amyloid cascade hypothesis an updated critica.pdf:application\/pdf;Snapshot:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\RP4YWL4C\\\\7162122.html:text\/html, May, 2023-09-14, Results from recent clinical trials of antibodies that target amyloid-$$\\beta$$ (A$\\beta$) for Alzheimer\u2019s disease have created excitement and have been heralded as corroboration of the amyloid cascade hypothesis. However, while A$\\beta$ may contribute to disease, genetic, clinical, imaging and biochemical data suggest a more complex aetiology.Here we review the history and weaknesses of the amyloid cascade hypothesis in view of the new evidence obtained from clinical trials of anti-amyloid antibodies. These trials indicate that the treatments have either no or uncertain clinical effect on cognition. Despite the importance of amyloid in the definition of Alzheimer\u2019s disease, we argue that the data point to A$\\beta$ playing a minor aetiological role.We also discuss data suggesting that the concerted activity of many pathogenic factors contribute to Alzheimer\u2019s disease and propose that evolving multi-factor disease models will better underpin the search for more effective strategies to treat the disease., https:\/\/doi.org\/10.1093\/brain\/awad159, The amyloid cascade hypothesis, 0006-8950","DOI":"10.1093\/brain\/awad159"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Lorenzen, Angela and Samosh, Jonathan and Vandewark, Kenneth and Anborgh, Pieter H. and Seah, Claudia and Magalhaes, Ana C. and Cregan, Sean P. and Ferguson, Stephen SG and Pasternak, Stephen H. (2010) Rapid and {Direct} {Transport} of {Cell} {Surface} {APP} to the {Lysosome} defines a novel selective pathway. Molecular Brain 3(1): 11 https:\/\/doi.org\/10.1186\/1756-6606-3-11, Full Text PDF:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\QARK2G2I\\\\Lorenzen et al. - 2010 - Rapid and Direct Transport of Cell Surface APP to .pdf:application\/pdf;Snapshot:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\6WUTMXTL\\\\1756-6606-3-11.html:text\/html, Amyloid Precursor Protein, Amyloid Precursor Protein Processing, Early Endosome, Late Endosome, Supplemental Movie, April, 2023-12-16, A central feature of Alzheimer's disease is the cleavage of the amyloid precursor protein (APP) to form beta-amyloid peptide (A$$\\beta$$) by the $\\beta$-secretase and $$\\gamma$$-secretase enzymes. Although this has been shown to occur after endocytosis of APP from the cell surface, the exact compartments of APP processing are not well defined. We have previously demonstrated that APP and $\\gamma$-secretase proteins and activity are highly enriched in purified rat liver lysosomes. In order to examine the lysosomal distribution and trafficking of APP in cultured cells, we generated constructs containing APP fused to a C-terminal fluorescent protein tag and N-terminal HA-epitope tag. These were co-transfected with a panel of fluorescent-protein tagged compartment markers., https:\/\/doi.org\/10.1186\/1756-6606-3-11, 1756-6606","DOI":"10.1186\/1756-6606-3-11"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Nixon, Ralph A. (2013) The role of autophagy in neurodegenerative disease. Nature Medicine 19(8): 983--997 https:\/\/doi.org\/10.1038\/nm.3232, Full Text PDF:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\PXE5LSZM\\\\Nixon - 2013 - The role of autophagy in neurodegenerative disease.pdf:application\/pdf, Alzheimer's disease, Number: 8 Publisher: Nature Publishing Group, August, 2024-02-23, en, This Review provides an overview of the role of autophagy, a key lysosomal degradative process, in neurodegenerative diseases. The study of various neurodegenerative diseases has shown that defects in autophagy can arise at different points in the pathway, and this has implications for the successful modulation of autophagy for therapeutic purposes. The Review also discusses the latest developments in targeting alterations in autophagy as a therapeutic strategy for neurodegenerative diseases., https:\/\/www.nature.com\/articles\/nm.3232, 1546-170X, 2013 Springer Nature America, Inc.","DOI":"10.1038\/nm.3232"},{"key":"ref28","unstructured":"Im, Eunju and Jiang, Ying and Stavrides, Philip H. and Darji, Sandipkumar and Erdjument-Bromage, Hediye and Neubert, Thomas A. and Choi, Jun Yong and Wegiel, Jerzy and Lee, Ju-Hyun and Nixon, Ralph A. (2023) Lysosomal dysfunction in {Down} syndrome and {Alzheimer} mouse models is caused by v-{ATPase} inhibition by {Tyr} $$^{\\textrm{682}}$$ -phosphorylated {APP} $$\\beta$${CTF}. Science Advances 9(30): eadg1925 https:\/\/doi.org\/10.1126\/sciadv.adg1925, Im et al. - 2023 - Lysosomal dysfunction in Down syndrome and Alzheim.pdf:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\U2E8IK9L\\\\Im et al. - 2023 - Lysosomal dysfunction in Down syndrome and Alzheim.pdf:application\/pdf, July, 2024-02-26, en, Lysosome dysfunction arises early and propels Alzheimer\u2019s disease (AD). Herein, we show that amyloid precursor protein (APP), linked to early-onset AD in Down syndrome (DS), acts directly via its $\\beta$-C-terminal fragment ($\\beta$CTF) to disrupt lysosomal vacuolar (H+)\u2013adenosine triphosphatase (v-ATPase) and acidification. In human DS fibroblasts, the phosphorylated682YENPTY internalization motif of APP-$\\beta$CTF binds selectively within a pocket of the v-ATPase V0a1 subunit cytoplasmic domain and competitively inhibits association of the V1 subcomplex of v-ATPase, thereby reducing its activity. Lowering APP-$\\beta$CTF Tyr682phosphorylation restores v-ATPase and lysosome function in DS fibroblasts and in vivo in brains of DS model mice. Notably, lowering APP-$\\beta$CTF Tyr682phosphorylation below normal constitutive levels boosts v-ATPase assembly and activity, suggesting that v-ATPase may also be modulated tonically by phospho-APP-$\\beta$CTF. Elevated APP-$\\beta$CTF Tyr682phosphorylation in two mouse AD models similarly disrupts v-ATPase function. These findings offer previously unknown insight into the pathogenic mechanism underlying faulty lysosomes in all forms of AD., Lysosomal acidification failure early in Alzheimer\u2019s Disease involves direct, selective v-ATPase inhibition by APP $\\beta$CTF., https:\/\/www.science.org\/doi\/10.1126\/sciadv.adg1925, 2375-2548"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Pasternak, Stephen Howard and Callahan, John William and Mahuran, Don Joseph (2003) The role of the endosomal\/ lysosomal system in amyloid-beta production and the pathophysiology of {Alzheimer}'s disease: {Reexamining} the spatial paradox from a lysosomal perspective. Journal of Alzheimer's Disease 6(1): 53--65 https:\/\/doi.org\/10.3233\/JAD-2004-6107, Pasternak et al. - 2003 - The role of the endosomal lysosomal system in amy.pdf:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\YCMDRITE\\\\Pasternak et al. - 2003 - The role of the endosomal lysosomal system in amy.pdf:application\/pdf, July, 2024-04-11, en, One of the hallmarks of Alzheimer \u2019s disease is the cerebral deposition of plaques composed of a 37 \u201343 amino acid amyloid-beta (A$$\\beta$$) peptide. A$\\beta$ is produced by the sequential proteolytic cleavage of an integral-membrane protein, amyloid $\\beta$-protein precursor (A$\\beta$PP), \ufb01rst by $\\beta$-secretase (BACE), and then by $$\\gamma$$-secretase, a complex containing presenilin and Nicastrin. Although these cleavages were originally documented to occur in the endosomal\/ lysosomal system, other lines of evidence suggest that the responsible proteins and activity reside in the ER or Golgi. This lack of intracellular co-localization of enzyme and substrate has been referred to as the spatial paradox of Alzheimer\u2019s disease. Here we will review the biology of the lysosome and the literature supporting the endosomal\/ lysosomal production of A$\\beta$. We will also examine some of the data supporting A$\\beta$ production in the biosynthetic compartments and demonstrate its compatibility with an endosomal\/ lysosomal model. Finally, we will discuss the possible role of the acidic environment of the lysosome in the amyloidogenic process, and review the evidence for intracellular amyloidogenesis preceding amyloid plaque formation., https:\/\/www.medra.org\/servlet\/aliasResolver?alias=iospress&doi=10.3233\/JAD-2004-6107, The role of the endosomal\/ lysosomal system in amyloid-beta production and the pathophysiology of {Alzheimer}'s disease, 18758908, 13872877","DOI":"10.3233\/JAD-2004-6107"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Dreyer, Robert N. and Bausch, Kathryn M. and Fracasso, Paul and Hammond, Lisa J. and Wunderlich, David and Wirak, Dana O. and Davis, Gary and Brini, Carla M. and Bucholz, Thomas M. and K\\\"onig, Michael E. and Tamburini, Paul P. (1994) Processing of the pre-$$\\beta$$-amyloid protein by cathepsin D is enhanced by a familiar Alzheimer's disease mutation. European Journal of Biochemistry","DOI":"10.1111\/j.1432-1033.1994.00265.x"},{"key":"#cr-split#-ref31.1","doi-asserted-by":"crossref","unstructured":"Goate, Alison and Chartier-Harlin, Marie-Christine and Mullan, Mike and Brown, Jeremy and Crawford, Fiona and Fidani, Liana and Giuffra, Luis and Haynes, Andrew and Irving, Nick and James, Louise and Mant, Rebecca and Newton, Phillippa and Rooke, Karen and Roques, Penelope and Talbot, Chris and Pericak-Vance, Margaret and Roses, Alien and Williamson, Robert and Rossor, Martin and Owen, Mike and Hardy, John (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial {Alzheimer}'s disease. Nature 349(6311): 704--706 https:\/\/doi.org\/10.1038\/349704a0, Full Text PDF:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\JYNFWR8B\\\\Goate et al. - 1991 - Segregation of a missense mutation in the amyloid .pdf:application\/pdf, Humanities and Social Sciences, multidisciplinary, Science, Publisher: Nature Publishing Group, February, 2025-03-04, en, A LOCUS segregating with familial Alzheimer's disease","DOI":"10.1038\/349704a0"},{"key":"#cr-split#-ref31.2","unstructured":"(AD) has been mapped to chromosome 21 (ref. 1), close to the amyloid precursor protein (APP) gene2 -5. Recombinants between the APP gene and the AD locus have been reported6 -8 which seemed to exclude it as the site of the mutation causing familial AD. But recent genetic analysis of a large number of AD families has demonstrated that the disease is heterogeneous9. Families with late-onset AD do not show linkage to chromosome 21 markers9,10. Some families with early-onset AD show linkage to chromosome 21 markers, but some do not8,9,11. This has led to the suggestion that there is non-allelic genetic heterogeneity even within early onset familial AD8,9. To avoid the problems that heterogeneity poses for genetic analysis, we have examined the cosegregation of AD and markers along the long arm of chromosome 21 in a single family with AD confirmed by autopsy. Here we demonstrate that in this kindred, which shows linkage to chromosome 21 markers, there is a point mutation in the APP gene. This mutation causes an amino-acid substitution (Val \u2192Ile) close to the carboxy terminus of the \u03b2-amyloid peptide. Screening other cases of familial AD revealed a second unrelated family in which this variant occurs. This suggests that some cases of AD could be caused by mutations in the APP gene., https:\/\/www.nature.com\/articles\/349704a0, 1476-4687, 1991 Springer Nature Limited"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Golde, T. E. and Estus, S. and Younkin, L. H. and Selkoe, D. J. and Younkin, S. G. (1992) Processing of the amyloid protein precursor to potentially amyloidogenic derivatives. Science (New York, N.Y.) 255(5045): 728--730 https:\/\/doi.org\/10.1126\/science.1738847, Processing of the amyloid protein precursor to potentially amyloidogenic derivatives:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\SLDE4M27\\\\out.pdf:application\/pdf, Ammonium Chloride, Amyloid, Amyloid beta-Protein Precursor, Base Sequence, Cell Line, Endopeptidases, Humans, Leupeptins, Lysosomes, Molecular Sequence Data, Mutagenesis, Peptide Fragments, Transfection, 1738847, February, eng, The approximately 120-kilodalton amyloid beta protein precursor (beta APP) is processed into a complex set of 8- to 12-kilodalton carboxyl-terminal derivatives that includes potentially amyloidogenic forms with the approximately 4-kilodalton amyloid beta protein (beta AP) at or near their amino terminus. In order to determine if these derivatives are processed in a secretory pathway or by the endosomal-lysosomal system, (i) deletion mutants that produce the normal set of carboxyl-terminal derivatives and shortened secreted derivatives were analyzed and (ii) the effect of inhibitors of endosomal-lysosomal processing was examined. In the secretory pathway, cleavage of the beta APP occurs at a single site within the beta AP to generate one secreted derivative and one nonamyloidogenic carboxyl-terminal fragment, whereas, in the endosomal-lysosomal system, a complex set of carboxyl-terminal derivatives is produced that includes the potentially amyloidogenic forms., 0036-8075","DOI":"10.1126\/science.1738847"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Haass, Christian and Koo, Edward H. and Mellon, Angela and Hung, Albert Y. and Selkoe, Dennis J. (1992) Targeting of cell-surface $$\\beta$$-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature 357(6378): 500--503 https:\/\/doi.org\/10.1038\/357500a0, Full Text PDF:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\Z2LESJBC\\\\Haass et al. - 1992 - Targeting of cell-surface $\\beta$-amyloid precursor prot.pdf:application\/pdf, Humanities and Social Sciences, multidisciplinary, Science, Publisher: Nature Publishing Group, June, 2024-04-11, en, PROGRESSIVE cerebral deposition of the amyloid $\\beta$-peptide is an early and invariant feature of Alzheimer's disease. The $\\beta$-peptide is released by proteolytic cleavages from the $\\beta$-amyloid precursor protein ($\\beta$APP)1, a membrane-spanning glycoprotein expressed in most mammalian cells. Normal secretion of $\\beta$APP involves a cleavage in the $\\beta$-peptide region2-3, releasing the soluble extramembranous portion4,5 and retaining a 10K C-terminal fragment in the membrane6. Because this secretory pathway precludes $\\beta$-amyloid formation, we searched for an alternative proteolytic processing pathway that can generate $\\beta$-peptide-bearing fragments from full-length $\\beta$ APP. Incubation of living human endothelial cells with a $\\beta$APP antibody revealed reinternalization of mature $\\beta$APP from the cell surface and its targeting to endosomes\/lysosomes. After cell-surface biotinylation, full-length biotinylated $\\beta$APP was recovered inside the cells. Purification of lysosomes directly demonstrated the presence of mature $\\beta$APP and an extensive array of $\\beta$-peptide-containing proteolytic products. Our results define a second processing pathway for $\\beta$APP and suggest that it may be responsible for generating amyloid-bearing fragments in Alzheimer's disease., https:\/\/www.nature.com\/articles\/357500a0, Targeting of cell-surface $\\beta$-amyloid precursor protein to lysosomes, 1476-4687, 1992 Springer Nature Limited","DOI":"10.1038\/357500a0"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Pasternak, Stephen H. and Bagshaw, Richard D. and Guiral, Marianne and Zhang, Sunqu and Ackerley, Cameron A. and Pak, Brian J. and Callahan, John W. and Mahuran, Don J. (2003) Presenilin-1, nicastrin, amyloid precursor protein, and gamma-secretase activity are co-localized in the lysosomal membrane. The Journal of Biological Chemistry 278(29): 26687--26694 https:\/\/doi.org\/10.1074\/jbc.m304009200, Full Text:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\7A32FK8D\\\\Pasternak et al. - 2003 - Presenilin-1, nicastrin, amyloid precursor protein.pdf:application\/pdf, Alzheimer Disease, Amino Acid Sequence, Amyloid beta-Protein Precursor, Amyloid Precursor Protein Secretases, Animals, Aspartic Acid Endopeptidases, Cell Fractionation, Endopeptidases, Endosomes, Humans, Intracellular Membranes, Lysosomes, Membrane Glycoproteins, Membrane Proteins, Microscopy, Immunoelectron, Models, Biological, Peptide Fragments, Polyethylene Glycols, Presenilin-1, Rats, Rats, Sprague-Dawley, Substrate Specificity, 12736250, July, eng, Alzheimer's disease (AD) is caused by the cerebral deposition of beta-amyloid (Abeta), a 38-43-amino acid peptide derived by proteolytic cleavage of the amyloid precursor protein (APP). Initial studies indicated that final cleavage of APP by the gamma-secretase (a complex containing presenilin and nicastrin) to produce Abeta occurred in the endosomal\/lysosomal system. However, other studies showing a predominant endoplasmic reticulum localization of the gamma-secretase proteins and a neutral pH optimum of in vitro gamma-secretase assays have challenged this conclusion. We have recently identified nicastrin as a major lysosomal membrane protein. In the present work, we use Western blotting and immunogold electron microscopy to demonstrate that significant amounts of mature nicastrin, presenilin-1, and APP are co-localized with lysosomal associated membrane protein-1 (cAMP-1) in the outer membranes of lysosomes. Furthermore, we demonstrate that these membranes contain an acidic gamma-secretase activity, which is immunoprecipitable with an antibody to nicastrin. These experiments establish APP, nicastrin, and presenilin-1 as resident lysosomal membrane proteins and indicate that gamma-secretase is a lysosomal protease. These data reassert the importance of the lysosomal\/endosomal system in the generation of Abeta and suggest a role for lysosomes in the pathophysiology of AD., 0021-9258","DOI":"10.1074\/jbc.M304009200"},{"key":"ref35","unstructured":"Tam, Joshua H. K. and Seah, Claudia and Pasternak, Stephen H. (2014) The {Amyloid} {Precursor} {Protein} is rapidly transported from the {Golgi} apparatus to the lysosome and where it is processed into beta-amyloid. Molecular Brain 7: 54 https:\/\/doi.org\/10.1186\/s13041-014-0054-1, Full Text:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\IC58P5IH\\\\Tam et al. - 2014 - The Amyloid Precursor Protein is rapidly transport.pdf:application\/pdf, Adaptor Protein Complex 3, Amyloid beta-Peptides, Amyloid Precursor Protein Secretases, Animals, Cell Compartmentation, Cell Line, Gene Knockdown Techniques, Golgi Apparatus, Green Fluorescent Proteins, Lysosomal Membrane Proteins, Lysosomes, Mice, Mutation, Protein Binding, Protein Processing, Post-Translational, Protein Transport, RNA, Small Interfering, Staining and Labeling, PMC4237969, 25085554, August, eng, BACKGROUND: Alzheimer's disease (AD) is characterized by cerebral deposition of $$\\beta$$-amyloid peptide (A$\\beta$). A$\\beta$ is produced by sequential cleavage of the Amyloid Precursor Protein (APP) by $\\beta$- and $$\\gamma$$-secretases. Many studies have demonstrated that the internalization of APP from the cell surface can regulate A$\\beta$ production, although the exact organelle in which A$\\beta$ is produced remains contentious. A number of recent studies suggest that intracellular trafficking also plays a role in regulating A$\\beta$ production, but these pathways are relatively under-studied. The goal of this study was to elucidate the intracellular trafficking of APP, and to examine the site of intracellular APP processing.RESULTS: We have tagged APP on its C-terminal cytoplasmic tail with photoactivatable Green Fluorescent Protein (paGFP). By photoactivating APP-paGFP in the Golgi, using the Golgi marker Galactosyltranferase fused to Cyan Fluorescent Protein (GalT-CFP) as a target, we are able to follow a population of nascent APP molecules from the Golgi to downstream compartments identified with compartment markers tagged with red fluorescent protein (mRFP or mCherry); including rab5 (early endosomes) rab9 (late endosomes) and LAMP1 (lysosomes). Because $\\gamma$-cleavage of APP releases the cytoplasmic tail of APP including the photoactivated GFP, resulting in loss of fluorescence, we are able to visualize the cleavage of APP in these compartments. Using APP-paGFP, we show that APP is rapidly trafficked from the Golgi apparatus to the lysosome; where it is rapidly cleared. Chloroquine and the highly selective $\\gamma$-secretase inhibitor, L685, 458, cause the accumulation of APP in lysosomes implying that APP is being cleaved by secretases in the lysosome. The Swedish mutation dramatically increases the rate of lysosomal APP processing, which is also inhibited by chloroquine and L685, 458. By knocking down adaptor protein 3 (AP-3; a heterotetrameric protein complex required for trafficking many proteins to the lysosome) using siRNA, we are able to reduce this lysosomal transport. Blocking lysosomal transport of APP reduces A$\\beta$ production by more than a third.CONCLUSION: These data suggests that AP-3 mediates rapid delivery of APP to lysosomes, and that the lysosome is a likely site of A$\\beta$ production., 1756-6606"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Hatami, Asa and Monjazeb, Sanaz and Milton, Saskia and Glabe, Charles G. (2017) Familial {Alzheimer} \u2019s {Disease} {Mutations} within the {Amyloid} {Precursor} {Protein} {Alter} the {Aggregation} and {Conformation} of the {Amyloid}-$$\\beta$$ {Peptide}. Journal of Biological Chemistry 292(8): 3172--3185 https:\/\/doi.org\/10.1074\/jbc.M116.755264, Hatami et al. - 2017 - Familial Alzheimer\u2019s Disease Mutations within the .pdf:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\VTNTGSVG\\\\Hatami et al. - 2017 - Familial Alzheimer\u2019s Disease Mutations within the .pdf:application\/pdf, February, 2024-06-06, en, https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925820419179, 00219258","DOI":"10.1074\/jbc.M116.755264"},{"key":"ref37","unstructured":"Maesako, Masato and Houser, Mei C. Q. and Turchyna, Yuliia and Wolfe, Michael S. and Berezovska, Oksana (2022) Presenilin\/$$\\gamma$$-{Secretase} {Activity} {Is} {Located} in {Acidic} {Compartments} of {Live} {Neurons}. Journal of Neuroscience 42(1): 145--154 https:\/\/doi.org\/10.1523\/JNEUROSCI.1698-21.2021, Full Text PDF:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\HTZCPF8U\\\\Maesako et al. - 2022 - Presenilin$\\gamma$-Secretase Activity Is Located in Acid.pdf:application\/pdf, Alzheimer's disease, FRET, intracellular A$$\\beta$$, lysosomes, presenilin\/$\\gamma$-secretase, Publisher: Society for NeuroscienceSection: Research Articles, 34810230, January, 2024-06-12, en, Presenilin (PSEN)\/$\\gamma$-secretase is a protease complex responsible for the proteolytic processing of numerous substrates. These substrates include the amyloid precursor protein (APP), the cleavage of which by $\\gamma$-secretase results in the production of $\\beta$-amyloid (A$\\beta$) peptides. However, exactly where within the neuron $\\gamma$-secretase processes APP C99 to generate A$\\beta$ and APP intracellular domain (AICD) is still not fully understood. Here, we employ novel F\u00f6rster resonance energy transfer (FRET)-based multiplexed imaging assays to directly \u201cvisualize\u201d the subcellular compartment(s) in which $\\gamma$-secretase primarily cleaves C99 in mouse cortex primary neurons (from both male and female embryos). Our results demonstrate that $\\gamma$-secretase processes C99 mainly in LysoTracker-positive low-pH compartments. Using a new immunostaining protocol which distinguishes A$\\beta$ from C99, we also show that intracellular A$\\beta$ is significantly accumulated in the same subcellular loci. Furthermore, we found functional correlation between the endo-lysosomal pH and cellular $\\gamma$-secretase activity. Taken together, our findings are consistent with A$\\beta$ being produced from C99 by $\\gamma$-secretase within acidic compartments such as lysosomes and late endosomes in living neurons.SIGNIFICANCE STATEMENT Alzheimer's disease (AD) genetics and histopathology highlight the importance of amyloid precursor protein (APP) processing by $\\gamma$-secretase in pathogenesis. For the first time, this study has enabled us to directly \u201cvisualize\u201d that $\\gamma$-secretase processes C99 mainly in acidic compartments such as late endosomes and lysosomes in live neurons. Furthermore, we uncovered that intracellular $\\beta$-amyloid (A$\\beta$) is significantly accumulated in the same subcellular loci. Emerging evidence proposes the great importance of the endo-lysosomal pathway in mechanisms of misfolded proteins propagation (e.g., Tau, $$\\alpha$$-Syn). Therefore, the predominant processing of C99 and enrichment of A$\\beta$ in late endosomes and lysosomes may be critical events in the molecular cascade leading to AD., https:\/\/www-jneurosci-org.ucsf.idm.oclc.org\/content\/42\/1\/145, 0270-6474, 1529-2401, Copyright \u00a9 2022 the authors. SfN exclusive license."},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"de Medeiros, Liana M. and De Bastiani, Marco A. and Rico, Eduardo P. and Schonhofen, Patr \u00edcia and Pfaffenseller, Bianca and Wollenhaupt-Aguiar, Bianca and Grun, Lucas and Barb \u00e9-Tuana, Flor \u00eancia and Zimmer, Eduardo R. and Castro, Mauro A. A. and Parsons, Richard B. and Klamt, F \u00e1bio (2019) Cholinergic {Differentiation} of {Human} {Neuroblastoma} {SH}-{SY5Y} {Cell} {Line} and {Its} {Potential} {Use} as an {In} vitro {Model} for {Alzheimer} \u2019s {Disease} {Studies}. Molecular Neurobiology 56(11): 7355--7367 https:\/\/doi.org\/10.1007\/s12035-019-1605-3, Full Text PDF:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\CNPJWATK\\\\de Medeiros et al. - 2019 - Cholinergic Differentiation of Human Neuroblastoma.pdf:application\/pdf, SH-SY5Y, BDNF, Cholinergic neurons, Retinoic acid, November, 2024-11-13, en, Cholinergic transmission is critical to high-order brain functions such as memory, learning, and attention. Alzheimer \u2019s disease (AD) is characterized by cognitive decline associated with a specific degeneration of cholinergic neurons. No effective treatment to prevent or reverse the symptoms is known. Part of this might be due to the lack of in vitro models that effectively mimic the relevant features of AD. Here, we describe the characterization of an AD in vitro model using the SH-SY5Y cell line. Exponentially growing cells were maintained in DMEM\/F12 medium and differentiation was triggered by the combination of retinoic acid (RA) and BDNF. Both acetylcholinesterase (AChE) and choline acetyltransferase (ChAT) enzymatic activities and immunocontent were determined. For mimicking tau and amyloid- \u03b2 pathology, RA \u2009 + \u2009BDNF-differentiated cells were challenged with okadaic acid (OA) or soluble oligomers of amyloid- \u03b2 (A \u03b2Os) and neurotoxicity was evaluated. RA \u2009 + \u2009BDNF-induced differentiation resulted in remarkable neuronal morphology alterations characterized by increased neurite density. Enhanced expression and enzymatic activities of cholinergic markers were observed compared to RA-differentiation only. Combination of sublethal doses of A \u03b2Os and OA resulted in decreased neurite densities, an in vitro marker of synaptopathy. Challenging RA \u2009 + \u2009BDNF-differentiated SH-SY5Y cells with the combination of sublethal doses of OA and A \u03b2O, without causing considerable decrease of cell viability, provides an in vitro model which mimics the early-stage pathophysiology of cholinergic neurons affected by AD., https:\/\/doi.org\/10.1007\/s12035-019-1605-3, 1559-1182","DOI":"10.1007\/s12035-019-1605-3"},{"key":"ref39","unstructured":"Laqtom, Nouf N. and Dong, Wentao and Medoh, Uche N. and Cangelosi, Andrew L. and Dharamdasani, Vimisha and Chan, Sze Ham and Kunchok, Tenzin and Lewis, Caroline A. and Heinze, Ivonne and Tang, Rachel and Grimm, Christian and Dang Do, An N. and Porter, Forbes D. and Ori, Alessandro and Sabatini, David M. and Abu-Remaileh, Monther (2022) {CLN3} is required for the clearance of glycerophosphodiesters from lysosomes. Nature 609(7929): 1005--1011 https:\/\/doi.org\/10.1038\/s41586-022-05221-y, Full Text PDF:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\4AHAY89F\\\\Laqtom et al. - 2022 - CLN3 is required for the clearance of glycerophosp.pdf:application\/pdf, Lysosomes, Mechanisms of disease, Publisher: Nature Publishing Group, September, 2024-11-13, en, Lysosomes have many roles, including degrading macromolecules and signalling to the nucleus1. Lysosomal dysfunction occurs in various human conditions, such as common neurodegenerative diseases and monogenic lysosomal storage disorders (LSDs)2 \u20134. For most LSDs, the causal genes have been identified but, in some, the function of the implicated gene is unknown, in part because lysosomes occupy a small fraction of the cellular volume so that changes in lysosomal contents are difficult to detect. Here we develop the LysoTag mouse for the tissue-specific isolation of intact lysosomes that are compatible with the multimodal profiling of their contents. We used the LysoTag mouse to study CLN3, a lysosomal transmembrane protein with an unknown function. In children, the loss of CLN3 causes juvenile neuronal ceroid lipofuscinosis (Batten disease), a lethal neurodegenerative LSD. Untargeted metabolite profiling of lysosomes from the brains of mice lacking CLN3 revealed a massive accumulation of glycerophosphodiesters (GPDs) \u2014the end products of glycerophospholipid catabolism. GPDs also accumulate in the lysosomes of CLN3-deficient cultured cells and we show that CLN3 is required for their lysosomal egress. Loss of CLN3 also disrupts glycerophospholipid catabolism in the lysosome. Finally, we found elevated levels of glycerophosphoinositol in the cerebrospinal fluid of patients with Batten disease, suggesting the potential use of glycerophosphoinositol as a disease biomarker. Our results show that CLN3 is required for the lysosomal clearance of GPDs and reveal Batten disease as a neurodegenerative LSD with a defect in glycerophospholipid metabolism., https:\/\/www.nature.com\/articles\/s41586-022-05221-y, 1476-4687, 2022 The Author(s), under exclusive licence to Springer Nature Limited"},{"key":"ref40","unstructured":"McKendell, Alec K. and Houser, Mei C. Q. and Mitchell, Shane P. C. and Wolfe, Michael S. and Berezovska, Oksana and Maesako, Masato (2022) In-{Depth} {Characterization} of {Endo}-{Lysosomal} {A$$\\beta$$} in {Intact} {Neurons}. Biosensors 12(8): 663 https:\/\/doi.org\/10.3390\/bios12080663, Full Text PDF:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\76QPH7YI\\\\McKendell et al. - 2022 - In-Depth Characterization of Endo-Lysosomal A$\\beta$ in .pdf:application\/pdf, Alzheimer\u2019s disease, fluorescence resonance energy transfer (FRET), glycoconjugates, intracellular amyloid-beta (A$\\beta$), lysosomes, $$\\gamma$$-secretase, Number: 8Publisher: Multidisciplinary Digital Publishing Institute, August, 2024-06-12, en, Amyloid-beta (A$\\beta$) peptides are produced within neurons. Some peptides are released into the brain parenchyma, while others are retained inside the neurons. However, the detection of intracellular A$\\beta$ remains a challenge since antibodies against A$\\beta$ capture A$\\beta$ and its precursor proteins (i.e., APP and C99). To overcome this drawback, we recently developed 1) the C99 720-670 biosensor for recording $\\gamma$-secretase activity and 2) a unique multiplexed immunostaining platform that enables the selective detection of intracellular A$\\beta$ with subcellular resolution. Using these new assays, we showed that C99 is predominantly processed by $\\gamma$-secretase in late endosomes and lysosomes, and intracellular A$\\beta$ is enriched in the same subcellular loci in intact neurons. However, the detailed properties of A$\\beta$ in the acidic compartments remain unclear. Here, we report using fluorescent lifetime imaging microscopy (FLIM) that intracellular A$\\beta$ includes both long A$\\beta$ intermediates bound to $\\gamma$-secretase and short peptides dissociated from the protease complex. Surprisingly, our results also suggest that the dissociated A$\\beta$ is bound to the glycoproteins on the inner membrane of lysosomes. Furthermore, we show striking cell-to-cell heterogeneity in intracellular A$\\beta$ levels in primary neurons and APP transgenic mouse brains. These findings provide a basis for the further investigation of the role(s) of intracellular A$\\beta$ and its relevance to Alzheimer\u2019s disease (AD)., https:\/\/www.mdpi.com\/2079-6374\/12\/8\/663, 2079-6374, http:\/\/creativecommons.org\/licenses\/by\/3.0\/"},{"key":"ref41","unstructured":"Picone, Pasquale and Nuzzo, Domenico and Giacomazza, Daniela and Di Carlo, Marta (2020) $$\\beta$$-{Amyloid} {Peptide}: the {Cell} {Compartment} {Multi}-faceted {Interaction} in {Alzheimer}\u2019s {Disease}. Neurotoxicity Research 37(2): 250--263 https:\/\/doi.org\/10.1007\/s12640-019-00116-9, Full Text PDF:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\W33H5I6I\\\\Picone et al. - 2020 - $\\beta$-Amyloid Peptide the Cell Compartment Multi-face.pdf:application\/pdf, Alzheimer\u2019s disease, Amyloid aggregates, A$\\beta$ peptides, Cellular death, Cellular organelles, February, 2024-06-12, en, Alzheimer\u2019s disease (AD) is the most widespread form of dementia, characterized by memory loss and reduction of cognitive functions that strongly interfere with normal daily life. Numerous evidences show that aggregates of the amyloid beta peptide, formed by 39 to 42 amino acid residues (A$\\beta$39\u201343), from soluble small oligomers to large fibrils are characteristic markers of this pathology. However, AD is a complex disease and its neurodegenerative molecular mechanism is not yet fully understood. Growing evidence suggests a link between A$\\beta$ polymorphic nature, oligomers and fibrils, and specific mechanisms of neurodegeneration. The A$\\beta$ variable nature and its multiplicity of interactions with different proteins and organelles reflect the complexity of this pathology. In this review, we analyze the effects of the interaction between A$\\beta$ peptide and different cellular compartments in relation to the different kinds and sizes of amyloid aggregates. In particular, A$\\beta$ interaction with different cell structures such as the plasma membrane, mitochondria, lysosomes, nucleus, and endoplasmic reticulum is discussed. Further, we analyze the A$\\beta$ peptide ability to modify the structure and function of the target organelle, inducing alteration of its physiological role thus contributing to the pathological event. Dysfunction of cellular components terminating with the activation of the cellular death mechanism and subsequent neurodegeneration is also taken into consideration., https:\/\/doi.org\/10.1007\/s12640-019-00116-9, $\\beta$-{Amyloid} {Peptide}, 1476-3524"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Colacurcio, Daniel J. and Nixon, Ralph A. (2016) Disorders of lysosomal acidification \u2014{The} emerging role of v-{ATPase} in aging and neurodegenerative disease. Ageing Research Reviews 32: 75--88 https:\/\/doi.org\/10.1016\/j.arr.2016.05.004, Colacurcio and Nixon - 2016 - Disorders of lysosomal acidification \u2014The emerging .pdf:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\64UI4G82\\\\Colacurcio and Nixon - 2016 - Disorders of lysosomal acidification \u2014The emerging .pdf:application\/pdf, December, 2024-06-13, en, https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568163716300800, 15681637","DOI":"10.1016\/j.arr.2016.05.004"},{"key":"ref43","unstructured":"Sadik, G. and Kaji, H. and Takeda, K. and Yamagata, F. and Kameoka, Y. and Hashimoto, K. and Miyanaga, K. and Shinoda, T. (1999) In vitro processing of amyloid precursor protein by cathepsin {D}. The International Journal of Biochemistry & Cell Biology 31(11): 1327--1337 https:\/\/doi.org\/10.1016\/s1357-2725(99)00053-9, Sadik et al. - 1999 - In vitro processing of amyloid precursor protein b.pdf:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\FDMHLPUK\\\\Sadik et al. - 1999 - In vitro processing of amyloid precursor protein b.pdf:application\/pdf, Alzheimer Disease, Amino Acid Sequence, Amyloid beta-Protein Precursor, Animals, Base Sequence, Binding Sites, Brain, Cathepsin D, Cattle, Chromatography, High Pressure Liquid, DNA Primers, Humans, In Vitro Techniques, Molecular Sequence Data, Peptide Fragments, Protein Processing, Post-Translational, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, 10605825, November, eng, The formation of beta A4 amyloid in the brains of individuals with Alzheimer's disease requires the proteolytic cleavage of amyloid precursor protein. Several lines of evidence suggest that cathepsin D, the major lysosomal\/endosomal aspartic protease, may be involved in this process. In this work, we used a sensitive in vitro method of detection to investigate the role of cathepsin D in the proteolytic processing of a 100-amino acid C-terminal fragment (C100) inclusive of beta A4 and cytoplasmic domain of APP. Digestion of C100 with cathepsin D resulted in cleavage at the amyloidogenic gamma-cleavage sites. This occurred preferentially at Thr43-Val44 and at Ala42-Thr43, generating full length beta A4 43 and beta A4 42 amyloid peptides, respectively. Cathepsin D was also found to cleave the substrate at the following nonamyloidogenic sites; Leu34-Met35, Thr48-Leu49 and Leu49-Val50. A high concentration of cathepsin D resulted in cleavage also occurring at Phe19-Phe20, Phe20-Ala21 and Phe93-Phe94 of the C100, suggesting that these sites are somewhat less sensitive to the action of cathepsin D. Digestion of C100 using different solublizing agents indicated that the cleavage of C100 by cathepsin D is greatly influenced by the structural integrity of the substrate. However, our results suggest that cathepsin D could generate the pathogenic beta A4 amyloid peptides from its precursor in vitro, which may indicate a role in the amyloidogenesis of Alzheimer's disease., 1357-2725"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Andrew, Robert J. and Kellett, Katherine A. B. and Thinakaran, Gopal and Hooper, Nigel M. (2016) A {Greek} {Tragedy}: {The} {Growing} {Complexity} of {Alzheimer} {Amyloid} {Precursor} {Protein} {Proteolysis}*. Journal of Biological Chemistry 291(37): 19235--19244 https:\/\/doi.org\/10.1074\/jbc.R116.746032, Full Text:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\KDDKMWFI\\\\Andrew et al. - 2016 - A Greek Tragedy The Growing Complexity of Alzheim.pdf:application\/pdf;ScienceDirect Snapshot:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\G2F7P8MU\\\\S002192582036004X.html:text\/html, ADAM, ADAM10, Alzheimer disease, amyloid, amyloid precursor protein (APP), amyloid-beta (AB), beta-secretase 1 (BACE1), cathepsin B (CTSB), presenilin, protease, proteolysis, secretase, September, 2024-06-17, Proteolysis of the amyloid precursor protein (APP) liberates various fragments including the proposed initiator of Alzheimer disease-associated dysfunctions, amyloid-$$\\beta$$. However, recent evidence suggests that the accepted view of APP proteolysis by the canonical $$\\alpha$$-, $\\beta$-, and $$\\gamma$$-secretases is simplistic, with the discovery of a number of novel APP secretases (including \u03b4- and \u03b7-secretases, alternative $\\beta$-secretases) and additional metabolites, some of which may also cause synaptic dysfunction. Furthermore, various proteins have been identified that interact with APP and modulate its cleavage by the secretases. Here, we give an overview of the increasingly complex picture of APP proteolysis., https:\/\/www.sciencedirect.com\/science\/article\/pii\/S002192582036004X, A {Greek} {Tragedy}, 0021-9258","DOI":"10.1074\/jbc.R116.746032"},{"key":"ref45","unstructured":"Gallwitz, Lisa and Bleibaum, Florian and Voss, Matthias and Schweizer, Michaela and Spengler, Katharina and Winter, Dominic and Z \u00f6phel, Frederic and M \u00fcller, Stephan and Lichtenthaler, Stefan and Damme, Markus and Saftig, Paul (2024) Cellular depletion of major cathepsin proteases reveals their concerted activities for lysosomal proteolysis. Cellular and molecular life sciences: CMLS 81(1): 227 https:\/\/doi.org\/10.1007\/s00018-024-05274-4, Full Text:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\8IMFHZ2V\\\\Gallwitz et al. - 2024 - Cellular depletion of major cathepsin proteases re.pdf:application\/pdf, Amyloid beta-Protein Precursor, Amyloid precursor protein, Autophagy, Bulk proteolysis, Cathepsin L, Cathepsins, Cell Line, Tumor, Endocytosis, HeLa Cells, Humans, Lysosome, Lysosomes, Protease network, Proteolysis, Proteomics, PMC11111660, 38775843, May, eng, Proteins delivered by endocytosis or autophagy to lysosomes are degraded by exo- and endoproteases. In humans 15 lysosomal cathepsins (CTS) act as important physiological regulators. The cysteine proteases CTSB and CTSL and the aspartic protease CTSD are the most abundant and functional important lysosomal proteinases. Whereas their general functions in proteolysis in the lysosome, their individual substrate, cleavage specificity, and their possible sequential action on substrate proteins have been previously studied, their functional redundancy is still poorly understood. To address a possible common role of highly expressed and functional important CTS proteases, we generated CTSB-, CTSD-, CTSL-, and CTSBDL-triple deficient (KO) human neuroblastoma-derived SH-SY5Y cells and CTSB-, CTSD-, CTSL-, CTSZ and CTSBDLZ-quadruple deficient (KO) HeLa cells. These cells with a combined cathepsin deficiency exhibited enlarged lysosomes and accumulated lipofuscin-like storage material. The lack of the three (SH-SY5Y) or four (HeLa) major CTSs caused an impaired autophagic flux and reduced degradation of endocytosed albumin. Proteome analyses of parental and CTS-depleted cells revealed an enrichment of cleaved peptides, lysosome\/autophagy-associated proteins, and potentially endocytosed membrane proteins like the amyloid precursor protein (APP), which can be subject to endocytic degradation. Amino- and carboxyterminal APP fragments accumulated in the multiple CTS-deficient cells, suggesting that multiple CTS-mediated cleavage events regularly process APP. In summary, our analyses support the idea that different lysosomal cathepsins act in concert, have at least partially and functionally redundant substrates, regulate protein degradation in autophagy, and control cellular proteostasis, as exemplified by their involvement in the degradation of APP fragments., 1420-9071"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Wang, Haizhi and Sang, Nianli and Zhang, Can and Raghupathi, Ramesh and Tanzi, Rudolph E. and Saunders, Aleister (2015) Cathepsin {L} {Mediates} the {Degradation} of {Novel} {APP} {C}-{Terminal} {Fragments}. Biochemistry 54(18): 2806--2816 https:\/\/doi.org\/10.1021\/acs.biochem.5b00329, Full Text PDF:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\2F5PMST8\\\\Wang et al. - 2015 - Cathepsin L Mediates the Degradation of Novel APP .pdf:application\/pdf, Publisher: American Chemical Society, May, 2024-06-17, Alzheimer \u2019s disease (AD) is characterized by the deposition of amyloid $$\\beta$$ (A$\\beta$), a peptide generated from proteolytic processing of its precursor, amyloid precursor protein (APP). Canonical APP proteolysis occurs via $$\\alpha$$-, $\\beta$-, and $$\\gamma$$-secretases. APP is also actively degraded by protein degradation systems. By pharmacologically inhibiting protein degradation with ALLN, we observed an accumulation of several novel APP C-terminal fragments (CTFs). The two major novel CTFs migrated around 15 and 25 kDa and can be observed across multiple cell types. The process was independent of cytotoxicity or protein synthesis. We further determine that the accumulation of the novel CTFs is not mediated by proteasome or calpain inhibition, but by cathepsin L inhibition. Moreover, these novel CTFs are not generated by an increased amount of BACE. Here, we name the CTF of 25 kDa as \u03b7-CTF (eta-CTF). Our data suggest that under physiological conditions, a subset of APP undergoes alternative processing and the intermediate products, the 15 kDa CTFs, and the \u03b7-CTFs aret rapidly degraded and\/or processed via the protein degradation machinery, specifically, cathepsin L., https:\/\/doi.org\/10.1021\/acs.biochem.5b00329, 0006-2960","DOI":"10.1021\/acs.biochem.5b00329"},{"key":"ref47","unstructured":"Chen, Allen C. and Kim, Sumin and Shepardson, Nina and Patel, Sarvagna and Hong, Soyon and Selkoe, Dennis J. (2015) Physical and functional interaction between the $$\\alpha$$- and $$\\gamma$$-secretases: {A} new model of regulated intramembrane proteolysis. Journal of Cell Biology 211(6): 1157--1176 https:\/\/doi.org\/10.1083\/jcb.201502001, Full Text PDF:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\YEYSDFEB\\\\Chen et al. - 2015 - Physical and functional interaction between the $\\alpha$-.pdf:application\/pdf;Snapshot:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\85AYRL35\\\\Physical-and-functional-interaction-between-the.html:text\/html, December, 2024-07-16, Many single-transmembrane proteins are sequentially cleaved by ectodomain-shedding $\\alpha$-secretases and the $\\gamma$-secretase complex, a process called regulated intramembrane proteolysis (RIP). These cleavages are thought to be spatially and temporally separate. In contrast, we provide evidence for a hitherto unrecognized multiprotease complex containing both $\\alpha$- and $\\gamma$-secretase. ADAM10 (A10), the principal neuronal $\\alpha$-secretase, interacted and cofractionated with $\\gamma$-secretase endogenously in cells and mouse brain. A10 immunoprecipitation yielded $\\gamma$-secretase proteolytic activity and vice versa. In agreement, superresolution microscopy showed that portions of A10 and $\\gamma$-secretase colocalize. Moreover, multiple $\\gamma$-secretase inhibitors significantly increased $\\alpha$-secretase processing (r = \u22120.86) and decreased $$\\beta$$-secretase processing of $\\beta$-amyloid precursor protein. Select members of the tetraspanin web were important both in the association between A10 and $\\gamma$-secretase and the $\\gamma$\u2192$\\alpha$ feedback mechanism. Portions of endogenous BACE1 coimmunoprecipitated with $\\gamma$-secretase but not A10, suggesting that $\\beta$- and $\\alpha$-secretases can form distinct complexes with $\\gamma$-secretase. Thus, cells possess large multiprotease complexes capable of sequentially and efficiently processing transmembrane substrates through a spatially coordinated RIP mechanism., https:\/\/doi.org\/10.1083\/jcb.201502001, Physical and functional interaction between the $\\alpha$- and $\\gamma$-secretases, 0021-9525"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Koo, E.H. and Squazzo, S.L. (1994) Evidence that production and release of amyloid beta-protein involves the endocytic pathway. Journal of Biological Chemistry 269(26): 17386--17389 https:\/\/doi.org\/10.1016\/S0021-9258(17)32449-3, Koo and Squazzo - 1994 - Evidence that production and release of amyloid be.pdf:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\464DTR2B\\\\Koo and Squazzo - 1994 - Evidence that production and release of amyloid be.pdf:application\/pdf, July, 2024-07-17, en, https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925817324493, 00219258, https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/","DOI":"10.1016\/S0021-9258(17)32449-3"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Vassar, Robert and Bennett, Brian D. and Babu-Khan, Safura and Kahn, Steve and Mendiaz, Elizabeth A. and Denis, Paul and Teplow, David B. and Ross, Sandra and Amarante, Patricia and Loeloff, Richard and Luo, Yi and Fisher, Seth and Fuller, Janis and Edenson, Steven and Lile, Jackson and Jarosinski, Mark A. and Biere, Anja Leona and Curran, Eileen and Burgess, Teresa and Louis, Jean-Claude and Collins, Frank and Treanor, James and Rogers, Gary and Citron, Martin (1999) $$\\beta$$-{Secretase} {Cleavage} of {Alzheimer}'s {Amyloid} {Precursor} {Protein} by the {Transmembrane} {Aspartic} {Protease} {BACE}. Science 286(5440): 735--741 https:\/\/doi.org\/10.1126\/science.286.5440.735, Full Text PDF:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\JN4AR88U\\\\Vassar et al. - 1999 - $\\beta$-Secretase Cleavage of Alzheimer's Amyloid Precur.pdf:application\/pdf, Publisher: American Association for the Advancement of Science, October, 2024-07-29, Cerebral deposition of amyloid $\\beta$ peptide (A$\\beta$) is an early and critical feature of Alzheimer's disease. A$\\beta$ generation depends on proteolytic cleavage of the amyloid precursor protein (APP) by two unknown proteases: $\\beta$-secretase and $$\\gamma$$-secretase. These proteases are prime therapeutic targets. A transmembrane aspartic protease with all the known characteristics of $\\beta$-secretase was cloned and characterized. Overexpression of this protease, termed BACE (for beta-site APP-cleaving enzyme) increased the amount of $\\beta$-secretase cleavage products, and these were cleaved exactly and only at known $\\beta$-secretase positions. Antisense inhibition of endogenous BACE messenger RNA decreased the amount of $\\beta$-secretase cleavage products, and purified BACE protein cleaved APP-derived substrates with the same sequence specificity as $\\beta$-secretase. Finally, the expression pattern and subcellular localization of BACE were consistent with that expected for $\\beta$-secretase. Future development of BACE inhibitors may prove beneficial for the treatment of Alzheimer's disease., https:\/\/www.science.org\/doi\/full\/10.1126\/science.286.5440.735","DOI":"10.1126\/science.286.5440.735"},{"key":"ref50","unstructured":"Kaur, G. and Pawlik, M. and Gandy, S. E. and Ehrlich, M. E. and Smiley, J. F. and Levy, E. (2017) Lysosomal dysfunction in the brain of a mouse model with intraneuronal accumulation of carboxyl terminal fragments of the amyloid precursor protein. Molecular Psychiatry 22(7): 981--989 https:\/\/doi.org\/10.1038\/mp.2016.189, Full Text PDF:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\BCUF94H4\\\\Kaur et al. - 2017 - Lysosomal dysfunction in the brain of a mouse mode.pdf:application\/pdf, Biochemistry, Molecular biology, Neuroscience, Publisher: Nature Publishing Group, July, 2024-08-07, en, Recent data suggest that intraneuronal accumulation of metabolites of the amyloid-$$\\beta$$-precursor protein (APP) is neurotoxic. We observed that transgenic mice overexpressing in neurons a human APP gene harboring the APPE693Q (Dutch) mutation have intraneuronal lysosomal accumulation of APP carboxylterminal fragments (APP-CTFs) and oligomeric amyloid $\\beta$ (oA$\\beta$) but no histological evidence of amyloid deposition. Morphometric quantification using the lysosomal marker protein 2 (LAMP-2) immunolabeling showed higher neuronal lysosomal counts in brain of 12-months-old APPE693Q as compared with age-matched non-transgenic littermates, and western blots showed increased lysosomal proteins including LAMP-2, cathepsin D and LC3. At 24 months of age, these mice also exhibited an accumulation of $$\\alpha$$-synuclein in the brain, along with increased conversion of LC3-I to LC3-II, an autophagosomal\/autolysosomal marker. In addition to lysosomal changes at 12 months of age, these mice developed cholinergic neuronal loss in the basal forebrain, GABAergic neuronal loss in the cortex, hippocampus and basal forebrain and gliosis and microgliosis in the hippocampus. These findings suggest a role for the intraneuronal accumulation of oA$\\beta$ and APP-CTFs and resultant lysosomal pathology at early stages of Alzheimer\u2019s disease-related pathology., https:\/\/www.nature.com\/articles\/mp2016189, 1476-5578, 2016 Macmillan Publishers Limited, part of Springer Nature."},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Vingtdeux, Val \u00e9rie and Hamdane, Malika and B \u00e9gard, S \u00e9verine and Loyens, Anne and Delacourte, Andr \u00e9 and Beauvillain, Jean-Claude and Bu \u00e9e, Luc and Marambaud, Philippe and Sergeant, Nicolas (2007) Intracellular {pH} regulates amyloid precursor protein intracellular domain accumulation. Neurobiology of Disease 25(3): 686--696 https:\/\/doi.org\/10.1016\/j.nbd.2006.09.019, Vingtdeux et al. - 2007 - Intracellular pH regulates amyloid precursor prote.pdf:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\ES4YRRXB\\\\Vingtdeux et al. - 2007 - Intracellular pH regulates amyloid precursor prote.pdf:application\/pdf, March, 2024-09-04, en, https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996106003044, 09699961, https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/","DOI":"10.1016\/j.nbd.2006.09.019"},{"key":"ref52","unstructured":"Bretou, Marine and Sannerud, Ragna and Escamilla-Ayala, Abril and Leroy, Tom and Vrancx, C \u00e9line and Van Acker, Zo \u00eb P. and Perdok, Anika and Vermeire, Wendy and Vorsters, Inge and Van Keymolen, Sophie and Maxson, Michelle and Pavie, Benjamin and Wierda, Keimpe and Eskelinen, Eeva-Liisa and Annaert, Wim (2024) Accumulation of {APP} {C}-terminal fragments causes endolysosomal dysfunction through the dysregulation of late endosome to lysosome-{ER} contact sites. Developmental Cell 59(12): 1571--1592.e9 https:\/\/doi.org\/10.1016\/j.devcel.2024.03.030, 1-s2.0-S1534580724001990-mmc1.pdf:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\8P2A2492\\\\1-s2.0-S1534580724001990-mmc1.pdf:application\/pdf;Bretou et al. - 2024 - Accumulation of APP C-terminal fragments causes en.pdf:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\RWVWKCH2\\\\Bretou et al. - 2024 - Accumulation of APP C-terminal fragments causes en.pdf:application\/pdf, June, 2024-09-04, en, Neuronal endosomal and lysosomal abnormalities are among the early changes observed in Alzheimer \u2019s disease (AD) before plaques appear. However, it is unclear whether distinct endolysosomal defects are temporally organized and how altered g-secretase function or amyloid precursor protein (APP) metabolism contribute to these changes. Inhibiting g-secretase chronically, in mouse embryonic  \ufb01broblast and hippocampal neurons, led to a gradual endolysosomal collapse initiated by decreased lysosomal calcium and increased cholesterol, causing downstream defects in endosomal recycling and maturation. This endolysosomal demise is g-secretase dependent, requires membrane-tethered APP cytoplasmic domains, and is rescued by APP depletion. APP C-terminal fragments (CTFs) localized to late endosome\/lysosome-endoplasmic reticulum contacts; an excess of APP-CTFs herein reduced lysosomal Ca2 + re \ufb01lling from the endoplasmic reticulum, promoting cholesterol accretion. Tonic regulation by APP-CTFs provides a mechanistic explanation for their cellular toxicity: failure to timely degrade APP-CTFs sustains downstream signaling, instigating lysosomal dyshomeostasis, as observed in prodromal AD. This is the opposite of substrates such as Notch, which require intramembrane proteolysis to initiate signaling., https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1534580724001990, 15345807"},{"key":"ref53","unstructured":"Oberstein, Timo Jan and Utz, Janine and Spitzer, Philipp and Klafki, Hans Wolfgang and Wiltfang, Jens and Lewczuk, Piotr and Kornhuber, Johannes and Maler, Juan Manuel (2020) The {Role} of {Cathepsin} {B} in the {Degradation} of {A$$\\beta$$} and in the {Production} of {A$\\beta$} {Peptides} {Starting} {With} {Ala2} in {Cultured} {Astrocytes}. Frontiers in Molecular Neuroscience 13: 615740 https:\/\/doi.org\/10.3389\/fnmol.2020.615740, Full Text:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\L937WCXD\\\\Oberstein et al. - 2020 - The Role of Cathepsin B in the Degradation of A$\\beta$ a.pdf:application\/pdf, Alzheimer's disease, amyloid beta, astrocytes, cathepsin B, lysosomal, N-terminus, PMC7836726, 33510618, eng, Astrocytes may not only be involved in the clearance of Amyloid beta peptides (A$\\beta$) in Alzheimer's disease (AD), but appear to produce N-terminally truncated A$\\beta$ (A$\\beta$n-x) independently of BACE1, which generates the N-Terminus of A$\\beta$ starting with Asp1 (A$\\beta$1-x). A candidate protease for the generation of A$\\beta$n-x is cathepsin B (CatB), especially since CatB has also been reported to degrade A$\\beta$, which could explain the opposite roles of astrocytes in AD. In this study, we investigated the influence of CatB inhibitors and the deletion of the gene encoding CatB (CTSB) using CRISPR\/Cas9 technology on A$\\beta$2-x and A$\\beta$1-x levels in cell culture supernatants by one- and two-dimensional Urea-SDS-PAGE followed by immunoblot. While the cell-permeant inhibitors E64d and CA-074 Me did not significantly affect the A$\\beta$1-x levels in supernatants of cultured chicken and human astrocytes, they did reduce the A$\\beta$2-x levels. In the glioma-derived cell line H4, the A$\\beta$2-x levels were likewise decreased in supernatants by treatment with the more specific, but cell-impermeant CatB-inhibitor CA-074, by CA-074 Me treatment, and by CTSB gene deletion. Additionally, a more than 2-fold increase in secreted A$\\beta$1-x was observed under the latter two conditions. The CA-074 Me-mediated increase of A$\\beta$1-x, but not the decrease of A$\\beta$2-x, was influenced by concomitant treatment with the vacuolar H+-ATPase inhibitor Bafilomycin A1. This indicated that non-lysosomal CatB mediated the production of A$\\beta$2-x in astrocytes, while the degradation of A$\\beta$1-x seemed to be dependent on lysosomal CatB in H4 cells, but not in primary astrocytes. These findings highlight the importance of considering organelle targeting in drug development to promote A$\\beta$ degradation., 1662-5099"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Lauritzen, Inger and Pardossi-Piquard, Rapha \u00eblle and Bourgeois, Alexandre and Pagnotta, Sophie and Biferi, Maria-Grazia and Barkats, Martine and Lacor, Pascale and Klein, William and Bauer, Charlotte and Checler, Frederic (2016) Intraneuronal aggregation of the $$\\beta$$-{CTF} fragment of {APP} ({C99}) induces {A$\\beta$}-independent lysosomal-autophagic pathology. Acta Neuropathologica 132(2): 257 https:\/\/doi.org\/10.1007\/s00401-016-1577-6, Full Text PDF:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\AHJN4J3J\\\\Lauritzen et al. - 2016 - Intraneuronal aggregation of the $\\beta$-CTF fragment of.pdf:application\/pdf, 27138984, April, 2024-10-23, en, Endosomal-autophagic-lysosomal (EAL) dysfunction is an early and prominent neuropathological feature of Alzheimers\u2019s disease, yet the exact molecular mechanisms contributing to this pathology remain undefined. By combined biochemical, ..., https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4947121\/","DOI":"10.1007\/s00401-016-1577-6"},{"key":"ref55","unstructured":"Kim, Meewhi and Bezprozvanny, Ilya (2023) Analysis of {Non}-{Amyloidogenic} {Mutations} in {APP} {Supports} {Loss} of {Function} {Hypothesis} of {Alzheimer} \u2019s {Disease}. International Journal of Molecular Sciences 24(3): 2092 https:\/\/doi.org\/10.3390\/ijms24032092, Full Text PDF:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\UHRK4I25\\\\Kim and Bezprozvanny - 2023 - Analysis of Non-Amyloidogenic Mutations in APP Sup.pdf:application\/pdf, Alzheimer \u2019s disease, APP, gamma-secretase, modeling, presenilins, Number: 3 Publisher: Multidisciplinary Digital Publishing Institute, January, 2024-12-05, en, Proteolytic processing of amyloid precursor protein (APP) plays a critical role in pathogenesis of Azheimer \u2019s disease (AD). Sequential cleavage of APP by $$\\beta$$- and $$\\gamma$$-secretases leads to generation of A$\\beta$40 (non-amyloidogenic) and A$\\beta$42 (amyloidogenic) peptides. Presenilin-1 (PS1) or presenilin-2 (PS2) act as catalytic subunits of $\\gamma$-secretase. Multiple familial AD (FAD) mutations in APP, PS1, or PS2 affect APP proteolysis by $\\gamma$-secretase and influence levels of generated A$\\beta$40 and A$\\beta$42 peptides. The predominant idea in the field is the \u201camyloid hypothesis\u201d that states that the resulting increase in A$\\beta$42:A$\\beta$40 ratio leads to \u201ctoxic gain of function\u201d due to the accumulation of toxic A$\\beta$42 plaques and oligomers. An alternative hypothesis based on analysis of PS1 conditional knockout mice is that \u201closs of function\u201d of $\\gamma$-secretase plays an important role in AD pathogenesis. In the present paper, we propose a mechanistic hypothesis that may potentially reconcile these divergent ideas and observations. We propose that the presence of soluble A$\\beta$ peptides in endosomal lumen (and secreted to the extracellular space) is essential for synaptic and neuronal function. Based on structural modeling of A$\\beta$ peptides, we concluded that A$\\beta$42 peptides and A$\\beta$40 peptides containing non-amyloidogenic FAD mutations in APP have increased the energy of association with the membranes, resulting in reduced levels of soluble A$\\beta$ in endosomal compartments. Analysis of PS1-FAD mutations also revealed that all of these mutations lead to significant reduction in both total levels of A$\\beta$ produced and in the A$\\beta$40\/A$\\beta$42 ratio, suggesting that the concentration of soluble A$\\beta$ in the endosomal compartments is reduced as a result of these mutations. We further reasoned that similar changes in A$\\beta$ production may also occur as a result of age-related accumulation of cholesterol and lipid oxidation products in postsynaptic spines. Our analysis more easily reconciled with the \u201closs of $\\gamma$-secretase function\u201d hypothesis than with the \u201ctoxic gain of A$\\beta$42 function\u201d idea. These results may also explain why inhibitors of $\\beta$- and $\\gamma$- secretase failed in clinical trials, as these compounds are also expected to significantly reduce soluble A$\\beta$ levels in the endosomal compartments., https:\/\/www.mdpi.com\/1422-0067\/24\/3\/2092, 1422-0067, http:\/\/creativecommons.org\/licenses\/by\/3.0\/"},{"key":"ref56","unstructured":"P \u00e4ivi \u00f6, A and Jarvet, J and Gr \u00e4slund, A and Lannfelt, L and Westlind-Danielsson, A (2004) Unique {Physicochemical} {Profile} of $$\\beta$$-{Amyloid} {Peptide} {Variant} {A$\\beta$1}\u2013{40E22G} {Protofibrils}: {Conceivable} {Neuropathogen} in {Arctic} {Mutant} {Carriers}. Journal of Molecular Biology 339(1): 145--159 https:\/\/doi.org\/10.1016\/j.jmb.2004.03.028, P\u00e4ivi\u00f6 et al. - 2004 - Unique Physicochemical Profile of $\\beta$-Amyloid Peptid.pdf:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\NRY9RF56\\\\P\u00e4ivi\u00f6 et al. - 2004 - Unique Physicochemical Profile of $\\beta$-Amyloid Peptid.pdf:application\/pdf;ScienceDirect Snapshot:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\68R946FE\\\\S0022283604003237.html:text\/html, Alzheimer's disease, amyloid, Arctic mutation, kinetics, protofibrils, May, 2025-01-04, A new early-onset form of Alzheimer's disease (AD) was described recently where a point mutation was discovered in codon 693 of the $\\beta$-amyloid (A$\\beta$) precursor protein gene, the Arctic mutation. The mutation translates into a single amino acid substitution, glutamic acid\u2192glycine, in position 22 of the A$\\beta$ peptide. The mutation carriers have lower plasma levels of A$\\beta$ than normal, while in vitro studies show that A$\\beta$1\u201340E22G protofibril formation is significantly enhanced. We have explored the nature of the A$\\beta$1\u201340E22G peptide in more detail, in particular the protofibrils. Using size-exclusion chromatography (SEC) and circular dichroism spectroscopy (CD) kinetic and secondary structural characteristics were compared with other A$\\beta$1\u201340 peptides and the A$\\beta$12\u201328 fragment, all having single amino acid substitutions in position 22. We have found that A$\\beta$1\u201340E22G protofibrils are a group of comparatively stabile $\\beta$-sheet-containing oligomers with a heterogeneous size distribution, ranging from {\\textgreater}100 kDa to {\\textgreater}3000 kDa. Small A$\\beta$1\u201340E22G protofibrils are generated about 400 times faster than large ones. Salt promotes their formation, which significantly exceeds all the other peptides studied here, including the Dutch mutation A$\\beta$1\u201340E22Q. Position 22 substitutions had significant effects on aggregation kinetics of A$\\beta$1\u201340 and in A$\\beta$12\u201328, although the qualitative aspects of the effects differed between the native peptide and the fragment, as no protofibrils were formed by the fragments. The rank order of protofibril formation of A$\\beta$1\u201340 and its variants was the same as the rank order of the length of the nucleation\/lag phase of the A$\\beta$12\u201328 fragments, E22V{\\textgreater}E22A\u226bE22G{\\textgreater}E22Q\u226bE22, and correlated with the degree of hydrophobicity of the position 22 substituent. The molecular mass of peptide monomers and protofibrils were estimated better in SEC studies using linear rather than globular calibration standards. The characteristics of the A$\\beta$1\u201340E22G suggest an important role for the peptide in the neuropathogenesis in the Arctic form of AD., https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0022283604003237, Unique {Physicochemical} {Profile} of $\\beta$-{Amyloid} {Peptide} {Variant} {A$\\beta$1}\u2013{40E22G} {Protofibrils}, 0022-2836"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Whalen, Brian M. and Selkoe, Dennis J. and Hartley, Dean M. (2005) Small non-fibrillar assemblies of amyloid $$\\beta$$-protein bearing the {Arctic} mutation induce rapid neuritic degeneration. Neurobiology of Disease 20(2): 254--266 https:\/\/doi.org\/10.1016\/j.nbd.2005.03.007, ScienceDirect Snapshot:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\335BWKB9\\\\S0969996105000823.html:text\/html;Whalen et al. - 2005 - Small non-fibrillar assemblies of amyloid $\\beta$-protei.pdf:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\JQ56AGPR\\\\Whalen et al. - 2005 - Small non-fibrillar assemblies of amyloid $\\beta$-protei.pdf:application\/pdf, Aggregation, Alzheimer's disease, Amyloid $\\beta$-protein, Arctic mutation, Neurodegeneration, Neurofilaments, Oligomer, Primary neuron culture, Protofibril, November, 2025-01-04, Recent studies suggest that soluble intermediates formed during amyloid $\\beta$-protein (A$\\beta$) fibrillogenesis are neurotoxic. We studied early aggregation assemblies of wild-type and mutant A$\\beta$ bearing the E22G (\u201cArctic\u201d) familial Alzheimer's disease mutation. Using a novel method to present purified, disaggregated A$\\beta$ peptides to primary cortical neurons, the detailed temporal pattern of neurotoxicity was assessed. Neurons exposed to Arctic A$\\beta$ showed a progressive degeneration that was much more rapid than that with wild-type A$\\beta$, beginning in dendrites and axons and leading to frank cell death. This neurotoxicity paralleled the aggregation process, with neuritic injury first appearing in the presence of small spherical A$\\beta$ oligomers, which were followed by a time-dependent elongation of curvilinear A$\\beta$ assemblies. One of the earliest neuritic changes was the formation of neurofilament-positive ringlets within axons, which disappeared as neurites followed by cell body degeneration. Our data support the hypothesis that small A$\\beta$ intermediates formed early in the aggregation process initiate cellular dysfunction beginning in neurites, leading to neuronal loss. A similar pattern of degeneration may occur during the preclinical and early clinical phases of Alzheimer's disease., https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0969996105000823, 0969-9961","DOI":"10.1016\/j.nbd.2005.03.007"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Reinhard, Constanze and H \u00e9bert, S \u00e9bastien S and De Strooper, Bart (2005) The amyloid \u2010$$\\beta$$ precursor protein: integrating structure with biological function. The EMBO Journal 24(23): 3996--4006 https:\/\/doi.org\/10.1038\/sj.emboj.7600860, Full Text:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\TFZEDWLL\\\\Reinhard et al. - 2005 - The amyloid\u2010$\\beta$ precursor protein integrating struc.pdf:application\/pdf, Alzheimer's disease, amyloid\u2010$\\beta$ precursor protein, APP, structural and functional relationships, Num Pages: 4006Publisher: John Wiley \\& Sons, Ltd, December, 2025-01-06, Proteolytic processing of the amyloid\u2010$\\beta$ precursor protein (APP) generates the A$\\beta$ amyloid peptide of Alzheimer's disease. The biological function of APP itself remains, however, unclear. In the current review, we study in detail the different subdomains of APP and try to assign functional significance to particular structures identified in the protein., https:\/\/www.embopress.org\/doi\/full\/10.1038\/sj.emboj.7600860, The amyloid\u2010$\\beta$ precursor protein, 0261-4189","DOI":"10.1038\/sj.emboj.7600860"},{"key":"ref59","unstructured":"Kamino, K. and Orr, H. T. and Payami, H. and Wijsman, E. M. and Alonso, M. E. and Pulst, S. M. and Anderson, L. and O'dahl, S. and Nemens, E. and White, J. A. (1992) Linkage and mutational analysis of familial {Alzheimer} disease kindreds for the {APP} gene region. American Journal of Human Genetics 51(5): 998--1014 Adult, Aged, Aged, 80 and over, Alzheimer Disease, Amino Acid Sequence, Amyloid beta-Protein Precursor, Base Sequence, Blotting, Southern, Chromosomes, Human, Pair 21, Female, Humans, Lod Score, Male, Middle Aged, Molecular Sequence Data, Oligodeoxyribonucleotides, Pedigree, Polymerase Chain Reaction, PMC1682859, 1415269, November, eng, A large number of familial Alzheimer disease (FAD) kindreds were examined to determine whether mutations in the amyloid precursor protein (APP) gene could be responsible for the disease. Previous studies have identified three mutations at APP codon 717 which are pathogenic for Alzheimer disease (AD). Samples from affected subjects were examined for mutations in exons 16 and 17 of the APP gene. A combination of direct sequencing and single-strand conformational polymorphism analysis was used. Sporadic AD and normal controls were also examined by the same methods. Five sequence variants were identified. One variant at APP codon 693 resulted in a Glu--{\\textgreater}Gly change. This is the same codon as the hereditary cerebral hemorrhage with amyloidosis-Dutch type Glu--{\\textgreater}Gln mutation. Another single-base change at APP codon 708 did not alter the amino acid encoded at this site. Two point mutations and a 6-bp deletion were identified in the intronic sequences surrounding exon 17. None of the variants could be unambiguously determined to be responsible for FAD. The larger families were also analyzed by testing for linkage of FAD to a highly polymorphic short tandem repeat marker (D21S210) that is tightly linked to APP. Highly negative LOD scores were obtained for the family groups tested, and linkage was formally excluded beyond theta = .10 for the Volga German kindreds, theta = .20 for early-onset non-Volga Germans, and theta = .10 for late-onset families. LOD scores for linkage of FAD to markers centromeric to APP (D21S1\/S11, D21S13, and D21S215) were also negative in the three family groups. These studies show that APP mutations account for AD in only a small fraction of FAD kindreds., 0002-9297"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Nilsberth, Camilla and Westlind-Danielsson, Anita and Eckman, Christopher B. and Condron, Margaret M. and Axelman, Karin and Forsell, Charlotte and Stenh, Charlotte and Luthman, Johan and Teplow, David B. and Younkin, Steven G. and N \u00e4slund, Jan and Lannfelt, Lars (2001) The '{Arctic}' {APP} mutation ({E693G}) causes {Alzheimer}'s disease by enhanced {A$$\\beta$$} protofibril formation. Nature Neuroscience 4(9): 887--893 https:\/\/doi.org\/10.1038\/nn0901-887, Full Text PDF:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\35KKTGYZ\\\\Nilsberth et al. - 2001 - The 'Arctic' APP mutation (E693G) causes Alzheimer.pdf:application\/pdf, Animal Genetics and Genomics, Behavioral Sciences, Biological Techniques, Biomedicine, general, Neurobiology, Neurosciences, Publisher: Nature Publishing Group, September, 2025-02-13, en, Several pathogenic Alzheimer's disease (AD) mutations have been described, all of which cause increased amyloid $\\beta$-protein (A$\\beta$) levels. Here we present studies of a pathogenic amyloid precursor protein (APP) mutation, located within the A$\\beta$ sequence at codon 693 (E693G), that causes AD in a Swedish family. Carriers of this 'Arctic' mutation showed decreased A$\\beta$42 and A$\\beta$40 levels in plasma. Additionally, low levels of A$\\beta$42 were detected in conditioned media from cells transfected with APPE693G. Fibrillization studies demonstrated no difference in fibrillization rate, but A$\\beta$ with the Arctic mutation formed protofibrils at a much higher rate and in larger quantities than wild-type (wt) A$\\beta$. The finding of increased protofibril formation and decreased A$\\beta$ plasma levels in the Arctic AD may reflect an alternative pathogenic mechanism for AD involving rapid A$\\beta$ protofibril formation leading to accelerated buildup of insoluble A$\\beta$ intra- and\/or extracellularly., https:\/\/www.nature.com\/articles\/nn0901-887, 1546-1726, 2001 Springer Nature Limited","DOI":"10.1038\/nn0901-887"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Williamson, W. Ryan and Hiesinger, P. Robin (2010) On the role of v-{ATPase} {V0a1} \u2013dependent degradation in {Alzheimer} {Disease}. Communicative & Integrative Biology 3(6): 604--607 https:\/\/doi.org\/10.4161\/cib.3.6.13364, Full Text PDF:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\H4UJHKYS\\\\Williamson and Hiesinger - 2010 - On the role of v-ATPase V0a1 \u2013dependent degradation.pdf:application\/pdf, Publisher: Taylor & Francis \\_eprint: https:\/\/doi.org\/10.4161\/cib.3.6.13364, 21331254, November, 2025-03-04, Defective autophagy and lysosomal degradation are hallmarks of numerous neurodegenerative disorders. Vesicular ATPases are intracellular proton pumps that acidify autophagosomes and lysosomes. V0a1 is a key component of the v-ATPase that is only required in neurons in Drosophila melanogaster. We have recently shown that loss of V0a1 in Drosophila photoreceptor neurons leads to slow, adult-onset degeneration.1 Concurrently, Lee et al.2 reported that V0a1 fails to localize to lysosomal compartments in cells from Presenilin 1 knock-out cells. Together these two reports suggest that a neuronal V0a1-dependent degradation mechanism may be causally linked to Alzheimer pathology. Indeed, we now show that loss of V0a1 makes Drosophila neurons more susceptible to insult with human Alzheimer-related neurotoxic A$$\\beta$$ and tau proteins. Furthermore, we discuss the potential significance of the discovery of the neuron-specific degradation mechanism in Drosophila for intracellular degradation defects in Alzheimer Disease., https:\/\/doi.org\/10.4161\/cib.3.6.13364, null","DOI":"10.4161\/cib.3.6.13364"},{"key":"ref62","unstructured":"Dubos, Aline and Castells-Nobau, Anna and Meziane, Hamid and Oortveld, Merel A.W. and Houbaert, Xander and Iacono, Giovanni and Martin, Christelle and Mittelhaeuser, Christophe and Lalanne, Val \u00e9rie and Kramer, Jamie M. and Bhukel, Anuradha and Quentin, Christine and Slabbert, Jan and Verstreken, Patrik and Sigrist, Stefan J. and Messaddeq, Nadia and Birling, Marie-Christine and Selloum, Mohammed and Stunnenberg, Henk G. and Humeau, Yann and Schenck, Annette and Herault, Yann (2015) Conditional depletion of intellectual disability and {Parkinsonism} candidate gene {ATP6AP2} in fly and mouse induces cognitive impairment and neurodegeneration. Human Molecular Genetics 24(23): 6736--6755 https:\/\/doi.org\/10.1093\/hmg\/ddv380, Full Text PDF:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\T98K9A6A\\\\Dubos et al. - 2015 - Conditional depletion of intellectual disability a.pdf:application\/pdf;Snapshot:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\2MAIGBRU\\\\2385813.html:text\/html, December, 2025-03-04, ATP6AP2, an essential accessory component of the vacuolar H + ATPase (V-ATPase), has been associated with intellectual disability (ID) and Parkinsonism. ATP6AP2 has been implicated in several signalling pathways; however, little is known regarding its role in the nervous system. To decipher its function in behaviour and cognition, we generated and characterized conditional knockdowns of ATP6AP2 in the nervous system of Drosophila and mouse models. In Drosophila, ATP6AP2 knockdown induced defective phototaxis and vacuolated photoreceptor neurons and pigment cells when depleted in eyes and altered short- and long-term memory when depleted in the mushroom body. In mouse, conditional Atp6ap2 deletion in glutamatergic neurons (Atp6ap2Camk2aCre\/0 mice) caused increased spontaneous locomotor activity and altered fear memory. Both Drosophila ATP6AP2 knockdown and Atp6ap2Camk2aCre\/0 mice presented with presynaptic transmission defects, and with an abnormal number and morphology of synapses. In addition, Atp6ap2Camk2aCre\/0 mice showed autophagy defects that led to axonal and neuronal degeneration in the cortex and hippocampus. Surprisingly, axon myelination was affected in our mutant mice, and axonal transport alterations were observed in Drosophila. In accordance with the identified phenotypes across species, genome-wide transcriptome profiling of Atp6ap2Camk2aCre\/0 mouse hippocampi revealed dysregulation of genes involved in myelination, action potential, membrane-bound vesicles and motor behaviour. In summary, ATP6AP2 disruption in mouse and fly leads to cognitive impairment and neurodegeneration, mimicking aspects of the neuropathology associated with ATP6AP2 mutations in humans. Our results identify ATP6AP2 as an essential gene for the nervous system., https:\/\/doi.org\/10.1093\/hmg\/ddv380, 0964-6906"},{"key":"ref63","unstructured":"Wendt, Wiebke and Zhu, Xin-Ran and L \u00fcbbert, Hermann and Stichel, Christine C. (2007) Differential expression of cathepsin {X} in aging and pathological central nervous system of mice. Experimental Neurology 204(2): 525--540 https:\/\/doi.org\/10.1016\/j.expneurol.2007.01.007, ScienceDirect Snapshot:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\Q29F2E25\\\\S0014488607000222.html:text\/html, Alzheimer's disease, Amyotrophic lateral sclerosis, Cathepsin, Inflammation, Lysosome, Mouse, April, 2025-03-04, Increasing evidence of a fundamental influence of cathepsins on inflammation has drawn interest in a thorough understanding of their role in physiological and pathological processes. Even though the number of identified cathepsins has more than doubled in the last years, information about their expression, regulation and function in the brain is still incomplete. In the present study we analyzed the regional, cellular and subcellular localization and the activity of the recently discovered cathepsin X in the normal, developing and pathological mouse brain. Our results show that CATX is: (i) is expressed in almost all cells in the mouse brain with a preference for glial cells; (ii) already widely expressed early in development and age-dependently upregulated in amount and activity; (iii) prominently localized in the lysosomal system but also scattered in the somal cytoplasm in the aged brain; (iv) upregulated in numerous glial cells of degenerating brain regions in a transgenic mouse model of amyotrophic lateral sclerosis; and (v) associated with plaques in a transgenic mouse model and in Alzheimer patients. These results strongly suggest that cathepsin X is an important player in degenerative processes during normal aging and in pathological conditions., https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0014488607000222, 0014-4886"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Mullan, M. and Crawford, F. and Axelman, K. and Houlden, H. and Lilius, L. and Winblad, B. and Lannfelt, L. (1992) A pathogenic mutation for probable {Alzheimer}'s disease in the {APP} gene at the {N}-terminus of beta-amyloid. Nature Genetics 1(5): 345--347 https:\/\/doi.org\/10.1038\/ng0892-345, Alzheimer Disease, Amino Acid Sequence, Amyloid beta-Protein Precursor, Base Sequence, Brain, Codon, Exons, Female, Genetic Linkage, Genetic Variation, Humans, Male, Middle Aged, Molecular Sequence Data, Oligodeoxyribonucleotides, Pedigree, Point Mutation, Transcription, Genetic, 1302033, August, eng, Mutations at codon 717 in exon 17 of the beta-amyloid precursor protein (APP) gene have previously been shown to segregate with early onset Alzheimer's disease in some families. We have identified a double mutation at codons 670 and 671 (APP 770 transcript) in exon 16 which co-segregates with the disease in two large (probably related) early-onset Alzheimer's disease families from Sweden. Two base pair transversions (G to T, A to C) from the normal sequence predict Lys to Asn and Met to Leu amino acid substitutions at codons 670 and 671 of the APP transcript. This mutation occurs at the amino terminal of beta-amyloid and may be pathogenic because it occurs at or close to the endosomal\/lysosomal cleavage site of the molecule. Thus, pathogenic mutations in APP frame the beta-amyloid sequence., 1061-4036","DOI":"10.1038\/ng0892-345"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Grabowski, T. J. and Cho, H. S. and Vonsattel, J. P. and Rebeck, G. W. and Greenberg, S. M. (2001) Novel amyloid precursor protein mutation in an {Iowa} family with dementia and severe cerebral amyloid angiopathy. Annals of Neurology 49(6): 697--705 https:\/\/doi.org\/10.1002\/ana.1009, Age of Onset, Aged, Amino Acid Sequence, Amyloid beta-Protein Precursor, Autopsy, Base Sequence, Cerebral Amyloid Angiopathy, Dementia, DNA Mutational Analysis, Female, Genes, Dominant, Germany, Humans, Iowa, Magnetic Resonance Imaging, Male, Middle Aged, Mutation, Missense, Occipital Lobe, Pedigree, Tomography, X-Ray Computed, 11409420, June, eng, Several mutations in the amyloid precursor protein (APP) gene have been found to associate with pathologic deposition of the beta-amyloid peptide (Abeta) in neuritic plaques or in the walls of cerebral vessels. We report a mutation at a novel site in APP in a three-generation Iowa family with autosomal dominant dementia beginning in the sixth or seventh decade of life. The proband and an affected brother had progressive aphasic dementia, leukoencephalopathy, and occipital calcifications. Neuropathological examination of the proband revealed severe cerebral amyloid angiopathy, widespread neurofibrillary tangles, and unusually extensive distribution of Abeta40 in plaques. The affected brothers shared a missense mutation in APP, resulting in substitution of asparagine for aspartic acid at position 694. This site corresponds to residue 23 of Abeta, thus differing from familial Alzheimer's disease mutations, which occur outside the Abeta sequence. Restriction enzyme analysis of DNA from 94 unrelated patients with sporadic cerebral amyloid angiopathy-related hemorrhage found no other instances of this mutation. These results suggest a novel site within Abeta that may promote its deposition and toxicity., 0364-5134","DOI":"10.1002\/ana.1009"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"O'Donoghue, Anthony J. and Eroy-Reveles, A. Alegra and Knudsen, Giselle M. and Ingram, Jessica and Zhou, Min and Statnekov, Jacob B. and Greninger, Alexander L. and Hostetter, Daniel R. and Qu, Gang and Maltby, David A. and Anderson, Marc O. and DeRisi, Joseph L. and McKerrow, James H. and Burlingame, Alma L. and Craik, Charles S. (2012) Global identification of peptidase specificity by multiplex substrate profiling. Nature Methods 9(11): 1095--1100 https:\/\/doi.org\/10.1038\/nmeth.2182, Full Text PDF:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\LIGFAJTD\\\\O'Donoghue et al. - 2012 - Global identification of peptidase specificity by .pdf:application\/pdf, Library construction, Mass spectrometry, Proteomic analysis, Publisher: Nature Publishing Group, November, 2025-03-05, en, A synthetic peptide library in conjunction with liquid chromatography \u2013tandem mass spectrometry identifies the specificities of endo- and exopeptidases without requiring enrichment of substrates or products., https:\/\/www.nature.com\/articles\/nmeth.2182, 1548-7105, 2012 Springer Nature America, Inc.","DOI":"10.1038\/nmeth.2182"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Rawlings, Neil D and Barrett, Alan J and Thomas, Paul D and Huang, Xiaosong and Bateman, Alex and Finn, Robert D (2018) The {MEROPS} database of proteolytic enzymes, their substrates and inhibitors in 2017 and a comparison with peptidases in the {PANTHER} database. Nucleic Acids Research 46(D1): D624--D632 https:\/\/doi.org\/10.1093\/nar\/gkx1134, Full Text:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\JENEXTMI\\\\Rawlings et al. - 2018 - The MEROPS database of proteolytic enzymes, their .pdf:application\/pdf, January, 2025-03-05, en, http:\/\/academic.oup.com\/nar\/article\/46\/D1\/D624\/4626772, 0305-1048, 1362-4962, http:\/\/creativecommons.org\/licenses\/by\/4.0\/","DOI":"10.1093\/nar\/gkx1134"},{"key":"ref68","unstructured":"Schomburg, Ida and Chang, Antje and Ebeling, Christian and Gremse, Marion and Heldt, Christian and Huhn, Gregor and Schomburg, Dietmar (2004) {BRENDA}, the enzyme database: updates and major new developments. Nucleic Acids Research 32(Database issue): D431--433 https:\/\/doi.org\/10.1093\/nar\/gkh081, Full Text:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\TBQGRJHU\\\\Schomburg et al. - 2004 - BRENDA, the enzyme database updates and major new.pdf:application\/pdf, Animals, Databases, Protein, Enzymes, Humans, Information Storage and Retrieval, Internet, Ligands, Organ Specificity, Protein Conformation, Protein Transport, Substrate Specificity, Terminology as Topic, PMC308815, 14681450, January, eng, BRENDA (BRaunschweig ENzyme DAtabase) represents a comprehensive collection of enzyme and metabolic information, based on primary literature. The database contains data from at least 83,000 different enzymes from 9800 different organisms, classified in approximately 4200 EC numbers. BRENDA includes biochemical and molecular information on classification and nomenclature, reaction and specificity, functional parameters, occurrence, enzyme structure, application, engineering, stability, disease, isolation and preparation, links and literature references. The data are extracted and evaluated from approximately 46,000 references, which are linked to PubMed as long as the reference is cited in PubMed. In the past year BRENDA has undergone major changes including a large increase in updating speed with {\\textgreater}50% of all data updated in 2002 or in the first half of 2003, the development of a new EC-tree browser, a taxonomy-tree browser, a chemical substructure search engine for ligand structure, the development of controlled vocabulary, an ontology for some information fields and a thesaurus for ligand names. The database is accessible free of charge to the academic community at http:\/\/www.brenda. uni-koeln.de., {BRENDA}, the enzyme database, 1362-4962"},{"key":"ref69","unstructured":"Li, Chunyan and Wang, Xin and Li, Xuezhi and Qiu, Kaixin and Jiao, Fengjuan and Liu, Yidan and Kong, Qingxia and Liu, Yan and Wu, Yili (2019) Proteasome {Inhibition} {Activates} {Autophagy}-{Lysosome} {Pathway} {Associated} {With} {TFEB} {Dephosphorylation} and {Nuclear} {Translocation}. Frontiers in Cell and Developmental Biology 7 https:\/\/doi.org\/10.3389\/fcell.2019.00170, Full Text PDF:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\DMH96RCN\\\\Li et al. - 2019 - Proteasome Inhibition Activates Autophagy-Lysosome.pdf:application\/pdf, Autophagy-lysosome pathway, TFEB, TFEB dephosphorylation, TFEB nuclear translocation, Ubiquitin-Proteasome Pathway, Publisher: Frontiers, August, 2025-03-11, English, {\\textless}p{\\textgreater}Ubiquitin-proteasome pathway (UPS) and autophagy-lysosome pathway (ALP) are the two major protein degradation pathways, which are critical for proteostasis. Growing evidence indicates that proteasome inhibition-induced ALP activation is an adaptive response. Transcription Factor EB (TFEB) is a master regulator of ALP. However, the characteristics of TFEB and its role in proteasome inhibition-induced ALP activation are not fully investigated. Here we reported that the half-life of TFEB is around 13.5 h in neuronal-like cells, and TFEB is degraded through proteasome pathway in both neuronal-like and non-neuronal cells. Moreover, proteasome impairment not only promotes TFEB accumulation but also facilitates its dephosphorylation and nuclear translocation. In addition, proteasome inhibition-induced TFEB accumulation, dephosphorylation and nuclear translocation significantly increases the expression of a number of TFEB downstream genes involved in ALP activation, including microtubule-associated protein 1B light chain-3 (LC3), particularly LC3-II, cathepsin D and lysosomal-associated membrane protein 1 (LAMP1). Furthermore, we demonstrated that proteasome inhibition increases autophagosome biogenesis but not impairs autophagic flux. Our study advances the understanding of features of TFEB and indicates that TFEB might be a key mediator of proteasome impairment-induced ALP activation.{\\textless}\/p{\\textgreater}, https:\/\/www.frontiersin.org\/journals\/cell-and-developmental-biology\/articles\/10.3389\/fcell.2019.00170\/full, 2296-634X"},{"key":"ref70","unstructured":"H \u00e4mmerle, Barbara and Ya \u00f1ez, Yania and Palanca, Sarai and Ca \u00f1ete, Adela and Burks, Deborah J. and Castel, Victoria and Font de Mora, Jaime (2013) Targeting {Neuroblastoma} {Stem} {Cells} with {Retinoic} {Acid} and {Proteasome} {Inhibitor}. PLoS ONE 8(10): e76761 https:\/\/doi.org\/10.1371\/journal.pone.0076761, PubMed Central Full Text PDF:C\\:\\\\Users\\\\carol\\\\Zotero\\\\storage\\\\TH836QWA\\\\H \u00e4mmerle et al. - 2013 - Targeting Neuroblastoma Stem Cells with Retinoic A.pdf:application\/pdf, PMC3792090, 24116151, October, 2025-03-11, Background Neuroblastma cell lines contain a side-population of cells which express stemness markers. These stem-like cells may represent the potential underlying mechanism for resistance to conventional therapy and recurrence of neuroblastoma in patients.  Methodology\/Principal Findings To develop novel strategies for targeting the side-population of neurobastomas, we analyzed the effects of 13-cis-retinoic acid (RA) combined with the proteasome inhibitor MG132. The short-term action of the treatment was compared with effects after a 5-day recovery period during which both chemicals were withdrawn. RA induced growth arrest and differentiation of SH-SY5Y and SK-N-BE(2) neuroblastoma cell lines. Inhibition of the proteasome caused apoptosis in both cell lines, thus, revealing the critical role of this pathway in the regulated degradation of proteins involved in neuroblastoma proliferation and survival. The combination of RA with MG132 induced apoptosis in a dose-dependent manner, in addition to promoting G2\/M arrest in treated cultures. Interestingly, expression of stem cell markers such as Nestin, Sox2, and Oct4 were reduced after the recovery period of combined treatment as compared with untreated cells or treated cells with either compound alone. Consistent with this, neurosphere formation was significantly impaired by the combined treatment of RA and MG132.  Conclusions Given that stem-like cells are associated with resistant to conventional therapy and are thought to be responsible for relapse, our results suggest that dual therapy of RA and proteasome inhibitor might be beneficial for targeting the side-population of cells associated residual disease in high-risk neuroblastoma., https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3792090\/, 1932-6203"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6978813\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6978813\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T17:39:56Z","timestamp":1752169196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6978813\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":72,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-6978813\/v1","relation":{},"subject":[],"published":{"date-parts":[[2025,7,10]]},"subtype":"preprint"}}